OMB Number: 0920-0612 Expiration Date: 08/31/2022

WISEWOMAN Program

MDE Manual Edition 18.3

Public reporting burden of this collection of information is estimated to average 24 hours per program including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports, Clearance Officer, 1600 Clifton Road NE, MS D-74, Atlanta, GA 30333. Attn: PRA (0920-0612). Do not send the completed form to this address.

CONTENTS

1.	INTRODUCTION	
2.		
	a. Summary of Administrative MDEs	4
	b. Administrative MDE Specifications	5
	Item 1a: StFIPS	
	Item 1b: HdANSI	
	Item 1c: EnrollSiteID	
	Item 1d: ScreenSiteID	
	Item 2a: TimePer	
	Item 2b: NScreen	
	Item 2c: Type	
	Item 2d: Navigation	
	Item 3a: EncodeID	
3.	SCREENING AND ASSESSMENT MDE SPECIFICATIONS	
	a. Summary of Screening and Assessment MDEs	
	b. Screening and Assessment MDE Specifications	
	Item 3b: ResANSI	
	Item 3c: ZIP	
	Item 3d: MYBItem 3e: Latino	
	Item 3f: Race1	
	Item 3g: Race2	
	Item 3h: Education	
	Item 3i: Language	
	Item 4a: SRC	
	Item 4b: SRHA	
	Item 5a: Meds	
	Item 5b: Aspirin	
	Item 5c: MedAdhere	
	Item 5d: Monitored	
	Item 6a: BPHome	
	Item 6b: BPFreg	
	Item 6c: BPSend	
	Item 7a: FruitVeg	38
	Item 7b: Fish	
	Item 7c: Grains	40
	Item 7d: Sugar	41
	Item 7e: SaltWatch	
	Item 7f: AlcFreq	
	Item 7g: AlcDay	
	Item 8a: PA	
	Item 9a: Smoker	
	Item 10a: PHQ	
	Item 11a: Height	
	Item 11b: Weight	
	Item 11c: Waist	
	Item 12a: BPDate	
	Item 12b: SBP	
	Item 12c: DBP	54

		Item 13a: Fast	
		Item 14a: TotChol	
		Item 14b: HDL	
		Item 14d: Tright	
		Item 14d: TriglyItem 15a: Glucose	
		Item 15b: A1C	
		Item 16a: BPAlert	
		Item 16b: BPDiDate	69
4.	RIS	SK REDUCTION COUNSELING MDE SPECIFICATIONS	70
	a.	Summary of Risk Reduction Counseling MDEs	71
	b.	Risk Reduction Counseling MDE Specifications	72
		Item 17a: RRCComplete	
5.	HE	ALTHY BEHAVIOR SUPPORT SERVICES MDE SPECIFICATIONS	73
	a.	Summary of Healthy Behavior Support Services MDEs	74
	b.	Healthy Behavior Support Services MDE Specifications	75
		Item 18a: RefDate	
		Item 19a: LSPHCRec	
		Item 19b: InterventionItem 19c: LSPHCID	
		Item 20a: TobResDate	
		Item 20b: TobResType	
		Item 20c: TResComp	
ΑP	PEI	NDIX A: SCREENING DEFINITIONS AND SUBMISSION GUIDANCE	A.1
	Da	ta Submission Guidance	A.1
	Su	bmission Procedures	A.7
	Da	ta Confidentiality and Security	A.7
ΑP		NDIX B: DATA QUALITY AND VALIDATION	
	Va	lidation of Data	B.3
	Da	ta Validation Procedures and Forms	B.4
	Err	or Rate Calculation Method	B.5
	Va	lidation of Data Form	.B.6
	Pa	rticipant ID Change Form	B.7
	Со	rrection to Previous MDE File Form	.B.8
		pplemental Lifestyle Program and Health Coaching (LSP/HC) Session Spreadsheet	
AP		NDIX C: DATA ANALYSIS AND USE	
	Da	ta Summary Report Format and Content	C.3
		ta Use by CDC	
		tential Data Use by Funded Programs	
ΑP		NDIX D: TECHNICAL ASSISTANCE RESOURCES	
	٠.	pes of Technical Assistance Available	
		Ipdesk for Individualized Technical Assistance Requests	
		NDIX E: PERFORMANCE MEASURES	
AP	PEI	NDIX F: NUTRITIONAL PROMPTS	F.1

1. INTRODUCTION

This WISEWOMAN MDE Manual was written to provide guidance on the collection and submission of minimum data elements (MDEs) for the Well-Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN) Program of the Centers for Disease Control and Prevention (CDC). The Program currently funds recipients of the cooperative agreement ("recipients") across the United States to improve cardiovascular health among low-income, underinsured, and uninsured women 40 to 64 years of age. Recipients are required to collect and report MDEs as part of standardized data reporting for the WISEWOMAN Program. MDEs are used by CDC and its recipients to describe, monitor, and assess progress and performance.

The MDEs in this manual (Edition 18.3) received approval in August 2019 from the Federal Office of Management and Budget. This manual pertains to the cooperative agreement DP18-1816. Data for the 59 MDEs can be separated into several categories: Administrative, Screening and Assessment, Risk Reduction Counseling, and Healthy Behavior Support Services.

The MDE manual includes information about technical specifications for the MDE variables included in each of the categories, guidance for their submission, and conventions for processing the data. Specifications for each MDE include variable name, definition, format, source of data, denominator population, acceptable values, description, and use for data analysis. *Please note that the format provided is relevant for data submitted by recipients for a six-month reporting period.* Variables are reported for each participant. These values for each participant establishes a record for their screening visit. The manual is organized as follows:

- Administrative MDE Specifications. This category includes 9 MDE variables. It
 includes data about the recipient program, including its geography, provider sites,
 aggregate screenings, and unique IDs of women to assess their health over time.
- Screening and Assessment MDE Specifications. This category contains 42 required MDE variables. It includes data about participant demographics; cardiovascular health status and history; clinical assessment values; and medical treatment status.
- Risk Reduction Counseling MDE Specifications. This category contains 1 required MDE variable. It includes data about the risk reduction counseling received by participants from a provider discussing their CVD risk.
- Healthy Behavior Support Services MDE Specifications. This category contains 7
 required MDE variables. It includes data about the evidence-informed Lifestyle
 Program/Health Coaching sessions available and received by participants as well as
 referrals to community-based tobacco cessation resources.

¹ Throughout this document, capital "Program" refers to the CDC WISEWOMAN Program, and lower-case "program" refers to the CDC-funded state/tribal recipients.

- Appendix A—MDE Screening Definitions and Submission Guidance. Data are required to be submitted semiannually. This appendix details screening definitions and submission guidance.
- Appendix B—Data Quality and Validation. To promote high-quality, consistent data
 across recipients, several tools are provided for use by recipients prior to MDE
 submission and by CDC after submission. This appendix describes the various
 validation procedures that recipients can use prior to submission and that CDC uses to
 assess data quality. In addition, the method used to calculate the error rate is provided
 for MDE submission files.
- Appendix C—Data Analysis and Use. MDEs have several analytic purposes for CDC and recipients, including (1) promoting public health practice through continuous program improvement (2) measuring and improving program performance, (3) assessing program health outcomes through evaluation and (4) calculating Atherosclerotic Cardiovascular disease Risk (ASCVD). This appendix describes the summary report format and the content produced and provided to recipients after each submission. It also discusses use of the data by CDC as well as potential ways in which recipients can utilize the data.
- Appendix D—Technical Assistance Resources. Several technical assistance
 resources are available to support recipients' MDE data collection and reporting. This
 appendix describes the various types of technical assistance resources that recipients
 may access, including one-on-one technical assistance, group trainings, documents,
 and tools available on the WISEWOMAN website. It also describes the process for
 requesting individual technical assistance and the response process for CDC and the
 data contractor.
- **Appendix E—Performance Measures.** This appendix provides a list of the six Program performance measures for DP18-1816.
- Appendix F –Nutritional prompts. This appendix includes a supplemental handout with examples for MDE items sourced from American Heart Association's Life's Simple 7.

This manual is a living document that will be updated from time to time. When changes are made to it, CDC will notify recipients that the updated manual is available on the WISEWOMAN Data Management System website [https://wwwn.cdc.gov/wisewoman].

2. ADMINISTRATIVE MDE SPECIFICATIONS

This section provides recipients with the information necessary to support collection and reporting of administrative MDEs, which must be done according to the specifications provided in this section of the manual.

These variables provide key contextual information about the structure and operations of recipient programs and are essential to the services provided through the program. For each participant record, programs provide FIPS/ANSI code in order to perform geospatial analyses for public health purposes. In addition, for the six-month submission period recipients must report for each participant the enrollment site, screening site, the type of screening received, and unique participant ID. Missing or invalid values for these variables will be considered to be errors.

This section begins with a summary of the 9 required variables (Subsection a) and then provides the technical specifications for each variable (Subsection b).

a. Summary of Administrative MDEs

Item Number	Variable Name	Beginning Position	Variable Label	Туре
1a	StFIPS	1	State/Tribal FIPS code	Character
1b	HdANSI	3	ANSI Geographic code (provider)	Character
1c	EnrollSiteID	8	Enrollment site ID	Character
1d	ScreenSiteID	13	Screening site ID	Numeric
2a	TimePer	23	Time period of screening	Numeric
2b	NScreen	24	Number of screenings received by the participant	Numeric
2c	Туре	25	Type of screening visit	Numeric
2d	Navigation	26	Were the navigation services paid for by NBCCEDP funds, WISEWOMAN funds, Indian Health Services/ Tribal funds, or other funds?	Numeric
3a	EncodeID	27	Unique participant ID number	Character

b. Administrative MDE Specifications

Item 1a: StFIPS*	State/Tribal FIPS Code					
		This variable indicates the FIPS or tribal program code for the state or tribe where the administration of the program is located.				
FORMAT	Type:	Character	Other Format:	N/A		
	Item Length:	2	Justification:	Left		
	Field Length:	2	Beginning Position:	1		
	Leading Zeros:	Yes	Valid Range:	See values; cannot be		
	Static Field:	Yes		blank		
SOURCE	National FIPS Code L	ist				
DENOMINATOR POPULATION	The denominator inclusive screening	udes all WISEWC	DMAN participants with a Co	omplete/BP+ baseline		
VALUES AND DESCRIPTION	National FIPS Code	•	it (character) value represe e that is providing services	enting the identification of the to the participant.		
ANALYSIS AND USE	To calculate the number	per of women scr	eened by each state or triba	al program		
	To assess the reach of tribe	of the WISEWOM	AN Program nationally and	within a particular state or		
OTHER INFORMATION	The state FIPS codes are the Federal Information Processing Standard codes developed by the National Institute of Standards and Technology. The tribal program codes are codes assigned by CDC to be used by tribal programs in lieu of FIPS.					
	Programs should always record the FIPS code for the state or tribe where their program is located. This may differ from the FIPS code for the participant's state or tribe of residence if the participant resides in a state or tribe different from where the program is located. Any FIPS contact that is not the same as where the program is located will be flagged as an error.					

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 1b: HdANSI*	ANSI Geographic Code (Provider) This indicates the ANSI geographic code of the provider that conducts the WISEWOMAN screening office visit.					
FORMAT	Type:	N/A				
	Item Length:	5	Justification:	Left		
	Field Length:	5	Beginning Position:	3		
	Leading Zeros:	Yes	Valid Range:	Valid ANSI code		
	Static Field:	No				
SOURCE	National ANSI Code	List, Census Bur	eau			
DENOMINATOR POPULATION	The denominator inc	cludes all screenir	ngs			
VALUES AND DESCRIPTION	ANSI Geographic C		(character) value represen that conducts the screening	ting the geographic area of the goffice visit		
ANALYSIS AND USE	To assess whether p	programs and spe	cific providers are meeting	screening goals in targeted		
	To identify geograph	ic areas where w	omen have access to the W	VISEWOMAN Program		
	To provide information	0 1	•			
	To assist in identifying areas where there may be potential transportation barriers to accessing WISEWOMAN services					
OTHER INFORMATION	American National S	ANSI codes are the American National Standards Institute codes, which were developed by the American National Standards Institute. They are five-digit codes that represent states, counties, and statistically equivalent areas, along with American Indian and Alaska Native areas.				
		The first two digits of the provider ANSI geographic code should represent the state of the provider that conducts the screening office visit, and the last three digits should represent the				

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 1c: EnrollSiteID*	Enrollment Site ID							
item ic. Emonsited								
	i nis variable indicate	This variable indicates the site of a woman's enrollment into the WISEWOMAN Program.						
FORMAT	Type:	Character	Other Format:	N/A				
	Item Length:	5	Justification:	Left				
	Field Length:	5	Beginning Position:	8				
	Leading Zeros:	N/A	Valid Range:	Valid ZIP code; cannot be				
	Static Field:	Yes blank						
SOURCE	Not applicable; WISE	EWOMAN-specifi	c variable					
DENOMINATOR POPULATION	The denominator inconscreening	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening						
VALUES AND DESCRIPTION	Enrollment Site ID	Valid five enrolled	e-digit ZIP code for the loca	tion where the participant is				
ANALYSIS AND USE	To identify sites whe	re outreach and e	enrollment are occurring					
	To identify sites whe	re the Program is	being administered and pa	articipants are tracked				
	To track the number of WISEWOMAN participants enrolled at each WISEWOMAN enrollment site							
OTHER INFORMATION	This may be the ZIP	The enrollment site ID should be the ZIP code of the location where the participant is enrolled. This may be the ZIP code for a provider site location if a provider conducts enrollment, or the ZIP code of the recipient location if the recipient conducts enrollment of the participant.						

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 1d: ScreenSiteID*	Screening Site ID					
Screensiteid	This variable indicates the site where a woman received her WISEWOMAN screening.					
FORMAT	Type:	Numeric	N/A			
	Item Length:	10	Justification:	Right		
	Field Length:	10	Beginning Position:	13		
	Leading Zeros:	N/A	Valid Range:	Valid code for a screening		
	Static Field:	No		site; cannot be blank		
SOURCE	National Provider Ide	entifier				
DENOMINATOR POPULATION	The denominator inc	cludes all screen	ngs			
VALUES AND DESCRIPTION	Screening Site ID		epresenting a National Provi nducts the screening office v	der Identifier for the provider visit		
ANALYSIS AND USE	To identify the geog	raphic locations	of sites providing screening s	services to participants		
	To track the number site	of WISEWOMA	N participants screened at e	ach WISEWOMAN screening		
	To describe differen	ces in participan	t demographics or other cha	racteristics by screening site		
	To provide information for geospatial analysis					
	To identify the numb	To identify the number of screening providers in a given geographic area				
	To identify provider paystems of care such		ent of health systems and poressure control	roviders that use clinical		

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 2a: TimePer*	Time Period of Screening This variable indicates the 6-month time period of the screening for the participant.				
FORMAT	Type:	Numeric	Other Format:	N/A	
	Item Length:	1	Justification:	Right	
	Field Length:	1	Beginning Position:	23	
	Leading Zeros:	No	Valid Range:	See values; cannot be blank	
	Static Field:	Yes	·	,	
SOURCE	Not applicable; WISE	WOMAN-spe	cific variable		
DENOMINATOR POPULATION	The denominator incl	The denominator includes all Complete/BP+ baseline screenings			
VALUES AND	1 6-month period 1	Scree	ening took place between	09/30/18 and 03/31/19	
DESCRIPTION	2 6-month period 2 Screening took place between 04/01/19 and 09/29/19				
	3 6-month period 1 Screening took place between 09/30/19 and 03/31/20				
	4 6-month period 2 Screening took place between 04/01/20 and 09/29/20				
	5 6-month period 1 Screening took place between 09/30/20 and 03/31/21				
	6 6-month period 2 Screening took place between 04/01/21 and 09/29/21				
	7 6-month period 1 Screening took place between 09/30/21 and 03/31/22				
	8 6-month period 2	Scree	ening took place between	04/01/22 and 09/29/22	
	9 6-month period 1 Screening took place between 09/30/22 and 03/31/23				
	0 6-month period 2 Screening took place between 04/01/23 and 09/29/23				
ANALYSIS AND USE	To track the number of screenings for each participant.				
OTHER INFORMATION	Time period of screening should be provided for each participant screening.				

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 2b: NScreen*	Number of Screen	Number of Screenings Received by the Participant					
		This variable indicates the total number of screenings that the participant has received since the beginning of the cooperative agreement.					
FORMAT	Type:	Numeric	Other Format:	N/A			
	Item Length:	1 Justification: Right					
	Field Length:	1 Beginning Position: 24					
	Leading Zeros:	No Valid Range: Cannot be blank					
	Static Field:	No					
SOURCE	Not applicable; WIS	EWOMAN-speci	fic variable				
DENOMINATOR POPULATION	The denominator incorrection	cludes all WISEV	VOMAN participants with a C	Complete/BP+ baseline			
VALUES AND DESCRIPTION	Number of Visits Value representing the number of screenings that the participant has received since the beginning of this cooperative agreement (includes current screening).						
	Any values outside 1 to 8 will be flagged for a quality check						
ANALYSIS AND USE	To track the number of screenings/ follow-up screenings/rescreenings						
OTHER INFORMATION		This field should include the number of screenings that the participant has received since the beginning of the cooperative agreement.					

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 2c: Type*	Type of Screening \	Type of Screening Visit					
	This variable indicates whether the record represents a baseline screening visit, a rescreening visit, or a post-Lifestyle Program (LSP)/Health Coaching (HC) follow-up screening.						
FORMAT	Type:	Numeric	Other Format:	N/A			
	Item Length:	1	Justification:	Right			
	Field Length:	1	Beginning Position:	25			
	Leading Zeros:	No	Valid Range:	See values; cannot be blank			
	Static Field:	No					
SOURCE	Not applicable; WISE	EWOMAN-sp	ecific variable				
DENOMINATOR POPULATION	The denominator includes all screenings						
VALUES AND	1 Screening		Record represents a baseline screening visit				
DESCRIPTION	2 Rescreening		Record represents a rescreening visit				
	3 Follow-up screening – LSP/HC complete		Record represents a 4 to 6 week post-LSP/HC follow-up screening with a complete LSP/HC				
	4 Follow-up screening – LSP/HC incomplete		Record represents a 4 to 6 week post-LSP/HC follow-up screening with an incomplete LSP/HC				
	9 No answer recorded		No answer recorded				
			This value will be flagged as a	This value will be flagged as an error			
ANALYSIS AND USE	To assess the number	er of unique \	women served by the WISEWO	MAN Program			
	To track participants	screening va	llues over time				
	To link baseline scre	J	•				
	To assess participan	ts progress a	ifter completion of an LSP/HC				
OTHER INFORMATION	Baseline screenings, rescreenings, and follow-up screenings will be classified as comp blood pressure plus (BP+), or incomplete based on the definitions in Appendix A.						
	Rescreenings occur between 11 and 18 months following the previous screening/rescreening.						
			een 3 and no later than 11 mont 4 to 6 weeks after LSP/HC cor				

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 2d: Navigation*	Were the navigation services paid for by NBCCEDP funds, WISEWOMAN funds, Indian Health Services/ Tribal funds, or other funds?					
FORMAT	Type:	Nume	eric	Other Format:	N/A	
	Item Length:	•		Justification:	Right	
	Field Length:			Beginning Position:	26	
	Leading Zeros:	No		Valid Range:	See values; cannot be	
	Static Field:	No			blank	
SOURCE	Not applicable; WISE	IAMOW	N-specific	variable		
DENOMINATOR POPULATION	The denominator incl	ludes all	screening	s		
VALUES AND DESCRIPTION	1 NBCCEDP funds	5	Funding s	source for navigation serv	rices was paid by NBCCEDP	
	2 WISEWOMAN fu	ınds		source for navigation serv DMAN funds	rices was paid by	
	3 Indian Health Service/Tribal fu	ınds		source for navigation serv Tribal funds	rices was paid by Indian Health	
	4 Other funds		Funding	source for navigation serv	rices was paid by other funds	
	5 Not Applicable		Not applicable			
ANALYSIS AND USE	To track funding sources for navigation services for participants who receive healthy behavior support services through the federally-funded WISEWOMAN program					
OTHER INFORMATION	WISEWOMAN participants who receive healthy behavior support services (such as health coaching or lifestyle programs), but whose cardiovascular screenings are reimbursed through an alternative payment source other than WISEWOMAN are considered navigated.					

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Itama Oas Essandal D*	Unione Bantisin and	ID Normalis and						
Item 3a: EncodeID*	Unique Participant ID Number							
	This variable indicate	This variable indicates a woman's unique identification number.						
FORMAT	Type:	Character	Other Format:	N/A				
	Item Length:	15	Justification:	Left				
	Field Length:	15	Beginning Position:	27				
	Leading Zeros:	N/A	Valid Range:	Cannot be blank				
	Static Field:	Yes						
SOURCE	Not applicable; WISI	Not applicable; WISEWOMAN-specific variable						
DENOMINATOR POPULATION	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening							
VALUES AND DESCRIPTION	Unique Participant ID Value representing the unique identifier for a participant Number							
ANALYSIS AND USE	To assess the numb	er of unique wom	nen served by the WISEWO	MAN Program				
	To track participants	over time						
	To link baseline scre	enings with resci	reenings					
	To link screenings with risk reduction counseling, lifestyle programs, health coaching, and community-based resource referrals							
OTHER INFORMATION	A participant's unique ID should not change over time. If it does change, the program should provide the data contractor and Project Officer with a list of IDs that have changed at the time of data submission and upload a crosswalk of the previous participant unique IDs to the new participant unique IDs (see Appendix B).							

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

3. SCREENING AND ASSESSMENT MDE SPECIFICATIONS

The purpose of this section is to provide recipients with the information necessary to support collection and reporting of Screening and Assessment MDEs, which must be done according to the specifications provided in this section of the manual. Complete and BP+ records are determined by MDEs provided under the Screening and Assessment category. Complete records will be used to calculate Atherosclerotic Cardiovascular Disease (ASCVD) risk, conduct detailed outcome analyses on CVD risk factors, and measure program implementation. BP+ records only meet the minimum requirements to measure ASCVD risk.

For a record to be counted as a Complete or BP+ screening, it must have valid values for required MDEs. **Definitions of complete and BP+ screenings are provided in Appendix A.**

Recipients are required to report all records, including those records that do not meet screening requirements, and they will be used to account for WISEWOMAN resources, but will not be analyzed in MDE reports generated by CDC or counted toward screening goals unless additional documentation is provided.^{2,3}

Below is a summary of the 42 required variables in the Screening and Assessment file (Subsection a). After the summary, the technical specifications for each variable are provided (Subsection b).

_

² Screening goals are agreed upon between each recipient and CDC. The number of screenings used to assess progress toward meeting the screening goal is calculated as the number of records meeting minimum screening requirements (baseline, follow-up screening or rescreening).

³ If the program is unable to obtain or the participant refuses to allow measurements for height, weight, blood pressure reading, labs, or to complete the personal assessment history, the program may choose to submit an explanation for this situation to be considered as an acceptable screening record. See Appendix B for additional information on this process.

a. Summary of Screening and Assessment MDEs

ltem Number	Variable Name	Beginning Position	Variable Label	Туре
3b	ResANSI	42	ANSI geographic code of residence	Character
3c	ZIP	47	ZIP code of residence	Character
3d	MYB	52	Month and year of birth	Numeric
3e	Latino	58	Hispanic or Latino origin	Numeric
3f	Race1	59	Race: first race	Numeric
3g	Race2	60	Race: second race	Numeric
3h	Education	61	Education (highest grade completed)	Numeric
3i	Language	62	What is the primary language spoken in your home?	Numeric
4a	SRC	64	Which of the following conditions do you have: i. Hypertension, ii High cholesterol, iii Diabetes (Type 1 or Type 2)	Numeric
4b	SRHA	67	Have you had any of the following: i. Stroke/ transient ischemic attack (TIA), ii. Heart attack, iii. Coronary heart disease, iv Heart failure, v. Vascular disease (peripheral arterial disease), vi. Congenital heart disease and defects	Numeric
5a	Meds	73	Was medication prescribed to lower: i. Blood pressure, ii. Cholesterol (Statin), iii. Cholesterol (other prescribed medication), iv. Blood sugar	Numeric
5b	Aspirin	77	Are you taking aspirin daily to help prevent a heart attack or stroke?	Numeric
5c	MedAdhere	78	During the past 7 days, how many days did you take prescribed medication for the following conditions: i. High blood pressure $(0 - 7 \text{ days})$, ii. High cholesterol $(0 - 7 \text{ days})$, iii. High blood sugar $(0 - 7 \text{ days})$	Numeric
5d	Monitored	84	After being prescribed medication, on what date(s) did the participant have her blood pressure remeasured either by a healthcare provider, or with another community resource?	Numeric
6a	BPHome	108	Do you measure your blood pressure at home or using other calibrated sources?	Numeric
6b	BPFreq	109	How often do you measure your blood pressure at home or using other calibrated sources?	Numeric
6c	BPSend	110	Do you regularly share blood pressure readings with a health care provider for feedback?	Numeric
7a	FruitVeg	111	How many cups of fruits and vegetables do you eat in an average day?	Numeric
7b	Fish	113	Do you eat fish at least two times a week?	Numeric
7c	Grains	114	Thinking about all the servings of grain products you eat in a typical day, how many are whole grains?	Numeric
7d	Sugar	115	Do you drink less than 36 ounces (450 calories) of beverages with added sugars weekly?	Numeric
7e	SaltWatch	116	Are you currently watching or reducing your sodium or salt intake?	Numeric
7f	AlcFreq	117	In the past 7 days, how often do you have a drink containing alcohol?	Numeric
7g	AlcDay	119	How many alcoholic drinks, on average, do you consume during a day you drink?	Numeric
8a	PA	121	How many minutes of physical activity (exercise) do you get in a week?	Numeric

Item Number	Variable Name	Beginning Position	Variable Label	Туре
9a	Smoker	125	Do you smoke? Includes cigarettes, pipes, or cigars (smoked tobacco in any form)	Numeric
10a	PHQ	126	Over the past 2 weeks, how often have you been bothered by any of the following problems? i. Little interest or pleasure in doing things (not at all, several days, more than half, or nearly every	Numeric
			day)?ii. Feeling down, depressed, or hopeless (not at all, several days, more than half, or nearly every day)?	
11a	Height	128	Height, inches	Numeric
11b	Weight	130	Weight, pounds	Numeric
11c	Waist	133	Waist circumference, inches	Numeric
12a	BPDate	135	Clinical assessment date (office visit date)	Numeric
12b	SBP	143	Systolic blood pressure, mmHg	Numeric
12c	DBP	155	Diastolic blood pressure, mmHg	Numeric
13a	Fast	167	Fasting status	Numeric
14a	TotChol	168	Total cholesterol (fasting or nonfasting), mg/dL	Numeric
14b	HDL	171	HDL cholesterol (fasting or nonfasting), mg/dL	Numeric
14c	LDL	174	LDL cholesterol (fasting or nonfasting), mg/dL	Numeric
14d	Trigly	177	Triglycerides (fasting or nonfasting), mg/dL	Numeric
15a	Glucose	181	Glucose (fasting only), mg/dL	Numeric
15c	A1C	184	A1C percentage	Numeric
16a	BPAlert	188	Is a medical follow-up for blood pressure reading necessary?	Numeric
16b	BPDiDate	189	What is the date of the medically necessary follow- up appointment?	Numeric

b. Screening and Assessment MDE Specifications

Item 3b: ResANSI*	~ .	uphic Code of Residence indicates the ANSI geographic code of residence of the WISEWOMAN			
FORMAT	Type:	Character	Other Format:	N/A	
	Item Length:	5	Justification:	Left	
	Field Length:	5	Beginning Position:	42	
	Leading Zeros:	Yes	Valid Range:	Valid ANSI code;	
	Static Field:	No		cannot be blank	
SOURCE	National ANSI Code	e List			
DENOMINATOR POPULATION	The denominator in screening	cludes all WISEWO	MAN participants with a Comple	ete/BP+ baseline	
VALUES AND DESCRIPTION	ANSI Geographic Code Value representing the participant's geographic area of residence				
ANALYSIS AND USE	To assess whether programs are meeting screening goals in targeted geographic areas To identify the reach of the WISEWOMAN Program To assist in identifying areas where there may be potential transportation barriers to accessing WISEWOMAN services				
OTHER INFORMATION	ANSI codes are the American National Standards Institute codes, which were developed by the American National Standards Institute. They are five-digit codes that represent states, counties and statistically equivalent areas, along with American Indian and Alaska Native areas. The first two digits of the participant ANSI geographic code of residence should represent the state of residence for the participant, and the last three digits should represent the participant's county of residence. Both ANSI geographic area of residence and ZIP code of residence (3c: ZIP) are required. ZIP code of residence should correspond to the ANSI geographic code of residence, in that the ZIP code must represent a valid geographic area within the county. If a participant does not reside in the state where the program is located, the ANSI code from her actual state of residence should be recorded. ANSI geographic code of residence should be captured at the first screening visit of the submission period; if geographic code of residence changes during a submission period, the last code collected for the submission period should be recorded.				

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 3c: ZIP*	ZIP Code of Residence					
	This variable indicate	es the	participant's ZIP	code of residence.		
FORMAT	Type:	Ch	aracter	Other Format:	N/A	
	Item Length:	5		Justification:	Left	
	Field Length:	5		Beginning Position:	47	
	Leading Zeros:	Ye	s	Valid Range:	Valid Zip code;	
	Static Field:	No			cannot be blank	
SOURCE	National ZIP Code L	ist				
DENOMINATOR POPULATION	The denominator inconscreening	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening				
VALUES AND	ZIP Code of Residence Valid five-digit (character) ZIP code					
DESCRIPTION	99999 ^a No ZIP code recorded					
	This value will be flagged as an error					
ANALYSIS AND USE		-	-	creening goals in targeted g	geographic areas	
	To identify the reach			•		
				outside program state bound		
OTHER INFORMATION				gray should not appear on		
	presented to participants. They are provided for funded program use only. Both ANSI geographic code of residence (3b: ResANSI) and ZIP code of residence are required. ZIP code of residence should correspond to the county code of residence, in that to ZIP code must represent a valid geographic area within the county. ZIP code of residence must be recorded regardless of whether or not the woman resides in same state as the program. This information will be used in conjunction with geographic code.				of residence are of residence, in that the ne woman resides in the	
	residence to identify the area of residence for a woman. If a participant does not reside in the same state as the program, the ZIP code from her actual state of residence should be recorded.					
	ZIP code of residence should be captured at the first screening visit of the submission period; if ZIP code of residence changes during a submission period, the last code collected for the submission period should be recorded.					

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 3d: MYB*	Month and Year of Birth						
	This variable indicates the participant's month and year of birth.						
FORMAT	Type:	Type: Numeric		MMCCYY date			
	Item Length:	6	Justification:	Right			
	Field Length:	6	Beginning Position:	52			
	Leading Zeros:	Yes	Valid Range:	Valid date; cannot be			
	Static Field:	Yes		blank			
SOURCE	Not applicable; WIS	Not applicable; WISEWOMAN-specific variable					
DENOMINATOR POPULATION	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening						
VALUES AND	Month and Year of Birth Month and Year of Birth in MMCCYY format						
DESCRIPTION	Example: September 01, 1965 = 091965						
ANALYSIS AND USE	To estimate the age and office visit date		e will be calculated using the	month and year of birth			
	To assist in characte	erizing the population	reached by the WISEWOMAI	N Program			
	To provide data element required to determine participant's cardiovascular risk or risk score						
	To assess whether	the participants are wi	thin the Program's priority ag	e group			
OTHER INFORMATION	The priority population for the WISEWOMAN Program is women aged 40 to 64. Servic provided to women outside the priority age range will be monitored by CDC.						
	Month and year of birth at screening is required for a record to count as a complete or BP+ record. If MYB is blank, the record will not count as a complete or BP+ record, and the record will not count toward meeting a program's screening goal.						

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 3e: Latino*	Hispanic or Latino Origin This variable indicates whether the participant is of Hispanic or Latino origin.					
FORMAT	Type:	Numeric	Other Format:	N/A		
	Item Length:	1	Justification:	Right		
	Field Length:	1	Beginning Position:	58		
	Leading Zeros:	No	Valid Range:	See values; cannot		
	Static Field:	Yes		be blank		
SOURCE	United States Office	e of Management an	d Budget Guidelines			
DENOMINATOR POPULATION	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening					
VALUES AND	1 Yes	Participar	Participant reports that she is of Hispanic or Latino origin			
DESCRIPTION	2 No	Participar	nt reports that she is not of Hisp	anic or Latino origin		
	7 Unknown	Participar	Participant is unsure whether she is of Hispanic or Latino origin			
	9 No answer rec	orded ^a Participai origin	nt has not reported whether she	is of Hispanic or Latino		
		This value	e will be flagged as an error			
ANALYSIS AND USE	To assess the race	ethnicity of WISEW	DMAN participants			
	To analyze screening, lifestyle programs, and other variables by ethnicity					
	To assist in characterizing the population reached by the WISEWOMAN Program					
	To provide data element required to determine participant's cardiovascular risk or risk score					
OTHER INFORMATION	•		ed in gray should not appear on rided for funded program use or			

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 3f: Race1*	Race: First Race This variable indicates a race with which the participant identifies.				
FORMAT	Type:	Numerio	· · ·	N/A	
	Item Length:	1	Justification:	Right	
	Field Length:	1	Beginning Position:	59	
	Leading Zeros:	No	Valid Range:	See values; cannot	
	Static Field:	Yes		be blank	
SOURCE	United States Cens	sus Burea	au; United States Office of Management a	nd Budget Guidelines	
DENOMINATOR POPULATION	The denominator in screening	ncludes a	II WISEWOMAN participants with a Comp	lete/BP+ baseline	
VALUES AND	1 White		Participant identifies White as a race		
DESCRIPTION	2 Black or African American		Participant identifies Black or African American as a race		
	3 Asian		Participant identifies Asian as a race		
	4 Native Hawaiian or Other Pacific Islander		Participant identifies Native Hawaiian or Other Pacific Islander as a race		
	5 American India Alaska Native	an or	Participant identifies American Indian or Alaska Native as a race		
	7 Unknown		Participant does not know her race or does not identify with any of the races listed above		
			If a participant is Hispanic and does not identify a race, this code should be used		
	9 No answer rec	orded ^a	Race information is missing for the participant		
			Any race information gathered should be entered beginning with the Race1 field		
ANALYSIS AND USE			of WISEWOMAN participants		
		•	screening, lifestyle programs, and other va	-	
	To assist in characterizing the population reached by the WISEWOMAN Program To provide data element required to determine participant's cardiovascular risk or risk score				
OTHER INFORMATION	^a Codes and respor presented to partic If a participant iden	^a Codes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only. If a participant identifies more than one race, one race is recorded here and other race she			
	identifies is recorde	ed in the s	subsequent race field (3g: Race2).		

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 3g: Race2			a race	e with which	the participant identifies in ca	ses where a participant is
FORMAT	Type:		Nun	neric	Other Format:	N/A
		ength:	1		Justification:	Right
	Field I	Length:	1		Beginning Position:	60
		ng Zeros:	No		Valid Range:	See values; cannot
	Static	_	Yes		•	be blank
SOURCE	United	States Census E	Burea	u; United Sta	ates Office of Management ar	nd Budget Guidelines
DENOMINATOR POPULATION	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening					
VALUES AND DESCRIPTION	1 Wh	nite		-	identifies White as a race who has identified two or mo	re races can have this
		ack or African nerican			identifies Black or African An who has identified two or mo	
	3 Asian		Participant identifies Asian as a race Participant who has identified two or more races can have this value			
	4 Native Hawaiian or Other Pacific Islander			Participant identifies Native Hawaiian or Other Pacific Islander as a race Participant who has identified two or more races can have this value		
	5 American Indian or Alaska Native			Participant identifies American Indian or Alaska Native as a race Participant who has identified two or more races can have this value		
	7 Un	known		Participant the races I	oes not identify with any o	
	9 No	answer recorde	ed ^a	If race information is missing for Race2 Participant has not identified any race		
				Participant races	has identified one race and o	loes not identify other
					ant does not identify a secon hould be used for this field an	
ANALYSIS AND USE	To understand and analyze screening, lifestyle programs, and other variables by race To assist in characterizing the population reached by the WISEWOMAN Program					
OTHER INFORMATION	To provide data element required to determine participant's cardiovascular risk or risk score aCodes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only. If a participant identifies two races, one race is recorded in Race1 and a second race is recorded here.					

Item 3h: Education	Education (highest grade completed) This variable indicates the highest grade the participant completed.					
FORMAT	Type:	Num	eric	Other Format:	N/A	
	Item Length:	1		Justification:	Right	
	Field Length:	1		Beginning Position:	61	
	Leading Zeros:	No		Valid Range:	See values; cannot	
	Static Field:	No			be blank	
SOURCE	CDC Behavioral Risk F	actor S	Surveillance Sys	tem		
DENOMINATOR POPULATION	The denominator include screening	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening				
VALUES AND	1 <9th grade		Participant rep	orts that she did not atten	d high school	
DESCRIPTION	2 Some high school	l	Participant rep	orts she attended high sc	hool, but did not graduate	
	3 High school gradu or equivalent	uate	eports that she graduated from high school or has nt of a high school diploma, and she did not attend or higher education			
	4 Some college or higher		Participant reports that she attended one or more years of college and/or graduate school (e.g., college graduate, graduate degree)			
	7 Don't know/Not su	ure	Participant reports that she does not know the highest grade she completed This value will be flagged as a quality check			
	8 Don't want to ans	wer ^a	Participant do completed	es not want to answer the	highest grade she	
	9 No answer record	This value will be flagged as a quality check deda Education information is missing for the participant This value will be flagged as an error				
ANALYSIS AND USE	To assess the education	onal atta	ainment of wom	en in the WISEWOMAN p	opulation	
	To understand screening, lifestyle programs, and other variables by education status To help determine the literacy level needed for materials developed for recruitment, risk reduction counseling, lifestyle programs, health coaching, and community-based resources To assist in characterizing the population reached by the WISEWOMAN Program				recruitment, risk ity-based resources	
OTHER INFORMATION	^a Codes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only.					

Item 3i: Language	What is the primary language spoken in your home? This variable indicates the primary language spoken in the participant's home.							
FORMAT	Type:	Numeric	Other Format:	N/A				
	Item Length:	2	Justification:	Right				
	Field Length:	2	Beginning Position:	62				
	Leading Zeros:	Yes	Valid Range:	See values; cannot				
	Static Field:	Yes		be blank				
SOURCE	National Survey of (Children's Health						
DENOMINATOR POPULATION	The denominator in screening	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening						
VALUES AND DESCRIPTION	01 English	Participa her hom	ant identifies English as the prir ne	mary language spoken in				
	02 Spanish	Participa her hom	ant identifies Spanish as the pri ne	mary language spoken i				
	03 Arabic	Participa her hom	ant identifies Arabic as the prim ne	ary language spoken in				
	04 Chinese		Participant identifies Chinese as the primary language spoken in her home					
	05 French		Participant identifies French as the primary language spoken in her home					
	06 Italian	· · · · · · · · · · · · · · · · · · ·	Participant identifies Italian as the primary language spoken in her home					
	07 Japanese		Participant identifies Japanese as the primary language spoken in her home					
	08 Korean	· ·	Participant identifies Korean as the primary language spoken in her home					
	09 Polish		Participant identifies Polish as the primary language spoken in her home					
	10 Russian		Participant identifies Russian as the primary language spoken in her home					
	11 Tagalog		Participant identifies Tagalog as the primary language spoken inher home					
	12 Vietnamese		Participant identifies Vietnamese as the primary language spoken in her home					
	13 Creole		Participant identifies Creole as the primary language spoken in her home					
	14 Portuguese		Participant identifies Portuguese as the primary language spoken in her home					
	15 Hmong		Participant identifies Hmong as the primary language spoken in her home					
	16 Other Languag		ant identifies another language in her home (write-in response)					
	88 Don't want to a	spoken	Participant does not want to answer the primary language spoken in her home This value will be flagged as a quality check					
	99 No answer reco		language information is missin ue will be flagged as an error	g for the participant				

ANALYSIS AND USE	To assess the primary language of women in the WISEWOMAN population To provide context to potential the health literacy issues To assist in characterizing the population reached by the WISEWOMAN Program
OTHER INFORMATION	^a Codes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only.

Item 4a: SRC*	Which of the following conditions do you have: i. Hypertension ii. High cholesterol iii. Diabetes (Type 1 or Type 2) This variable indicates whether the participant has hypertension, high cholesterol, and/ or diabetes.					
FORMAT	Type:	Numeric	Other Format:	N/A		
	Item Length:	3	Justification:	Right		
	Field Length:	3	Beginning Position:	64		
	Leading Zeros: No		Valid Range:	See values; cannot be blank if		
	Static Field:	No		TYPE is 1, 2, 3 or 4 (baseline screening, rescreening or follow-up)		
SOURCE	American Heart As	sociation				
DENOMINATOR POPULATION	The denominator in screening	ncludes all \	WISEWOMAN participants w	ith a Complete/BP+ baseline		
VALUES AND	1 Yes		Participant has the condition	1		
DESCRIPTION	2 No		Participant does not have the	ne condition		
(CODE FOR EACH CONDITION)	7 Don't know/Not sure		Participant does not know whether she has condition This value will be flagged as a quality check			
	8 Don't want to answer ^a		Participant does not want to answer whether she has the condition			
			This value will be flagged as a quality check			
	9 No answer recorded ^a		No answer recorded			
			This value will be flagged as	s an error		
ANALYSIS AND USE	To understand the WISEWOMAN pop		ular disease risk factors of ind	dividual participants and the overall		
	previously diagnos	ed as oppo	sed to newly detected cases	esterol, and diabetes that have been among the WISEWOMAN population		
	To assess control of and improvements in blood pressure, cholesterol, and diabetes for newly and previously diagnosed women To provide data elements required to determine participant's cardiovascular risk score.					
OTHER	To provide data elements required to determine participant's cardiovascular risk score Guidance					
INFORMATION	^a Codes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only.					
	Each of the three positions in the SRC field corresponds to a specific condition. The first position aligns with the participant's hypertension history. The second position aligns with the participant's high cholesterol history. The third position aligns with the participant's diabetes history.					
	Programs should assess a participant's history for each condition and record the corresponding value in the appropriate position in the SRC field. For example, if a participant reports that she: (a) has hypertension, (b) does not have high cholesterol, and (c) is unsure whether she has diabetes, SRC should be recorded as '127' (corresponding to values of '1- Yes' in position 1, '2 – No' in position 2, and '7 – Don't know/ not sure' in position 3).					
	Some programs may have access to participants' medical charts. In some cases, the medical chart may show that a participant's diagnosis for hypertension, high blood cholesterol, and/or diabetes is inconsistent with her self-report. In these instances, if the medical record indicates that she has hypertension, high blood cholesterol, and/or diabetes, the program should recode the relevant position of SRC as '1 Yes.'					
	Hypertension, cholesterol, and diabetes history status is required for a record to count as complete or BP+. If any position of SRC is blank or coded as "9 No answer recorded," the record will not count as a complete or BP+ record, and the record will not count toward meeting a program's screening goal.					

program's screening goal.

*Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 4b: SRHA*	Have you had any of the fo	llowing:				
ILEIII 4D. SIXIIA	-					
	i. Stroke/ transient ischemic attack (TIA) ii. Heart attack					
	iii. Coronary heart dis	sease				
	iv. Heart failure					
		peripheral arterial disease)				
	vi. Congenital heart disease and defects					
	This variable indicates whether the participant has ever been diagnosed by a healthcare provider as having stroke/ TIA, heart attack, coronary heart disease, heart failure, vascular disease (peripheral arterial disease), and/ or congenital heart disease and defects.					
FORMAT	Type: Numeric	Other Format:	N/A			
	Item Length: 6	Justification:	Right			
	Field Length: 6	Beginning Position:	67			
	Leading Zeros: No	Valid Range:	See values; cannot be blank if			
	Static Field: No	vana rango.	TYPE is 1, 2, 3 or 4 (baseline screening, rescreening or follow-up)			
SOURCE	American Heart Association					
DENOMINATOR POPULATION	The denominator includes all screening	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline				
VALUES AND DESCRIPTION	1 Yes	Participant has been diagneral having the condition	Participant has been diagnosed by a healthcare provider as having the condition			
(CODE FOR EACH CONDITION)	2 No	Participant has never been diagnosed by a healthcare provider as having each condition				
	7 Don't know/Not sure	Participant does not know whether she has been diagnosed by a healthcare provider as having the condition				
		This value will be flagged as a quality check				
	8 Don't want to answer ^a	Participant does not want to answer whether she has been diagnosed by a healthcare provider as having the condition				
		This value will be flagged as a quality check				
	9 No answer recorded ^a	No answer recorded				
		This value will be flagged as an error				
ANALYSIS AND USE	To understand the history of cardiovascular disease among individual participants and the overall WISEWOMAN population					
	To assess the number of participants who have been previously diagnosed as having cardiovascular disease					
	To provide data elements red	quired to determine participan	t's cardiovascular risk			
OTHER INFORMATION	^a Codes and response options highlighted in gray should not appear on the data collection for presented to participants. They are provided for funded program use only.					
	Each of the six positions in the SRHA field corresponds to a specific condition. The first position aligns with the participant's history of stroke/ TIA. The second position aligns with the participant's history of heart attack. The third position aligns with the participant's history of coronary heart disease. The fourth position aligns with the participant's history of heart failure. The fifth position aligns with the participant's history of vascular disease. The sixth position aligns with the participant's history of congenital heart disease and defects. Programs should assess a participant's history for each condition and record the corresponding					
	value in the appropriate position in the SRHA field. For example, if a participant reports that she had a stroke, but did not have heart attack, coronary heart disease, heart failure, vascular disease (peripheral arterial disease), or congenital heart disease and defects, SRHA should be recorded as '122222' (corresponding to values of '1- Yes' in position 1 and '2 – No' in position 2 through position 6).					

OTHER INFORMATION (CONT.)

Some programs may have access to participants' medical charts. In some cases, the medical chart may show that a participant's diagnosis for one of the specified conditions is inconsistent with her self-report. In these instances, if the medical record indicates that she has had any one of these conditions, the program should recode the corresponding position of SRHA as '1 Yes.' History of each of the six conditions is required for a record to count as a complete or BP+ record. If any position of SRHA is blank or coded as "9 No answer recorded," the record will not count as a complete or BP+ record, and the record will not count toward meeting a program's screening goal.

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 5a: Meds*	Was medication prescribed to lower: i. Blood pressure ii. Cholesterol (Statin) iii. Cholesterol (other prescribed medication) iv. Blood sugar This variable indicates whether the participant was prescribed medication to lower her blood pressure, cholesterol, and/or blood sugar.					
FORMAT	Type: N	umeric	Other Format:	N/A		
	Item Length: 4		Justification:	Right		
	Field Length: 4		Beginning Position:	73		
	Leading Zeros: No	0	Valid Range:	See values; cannot		
	Static Field: No	0	be			
SOURCE	American Heart Association	on				
DENOMINATOR POPULATION	The denominator includes WISEWOMAN participants with hypertension (high blood pressure), high cholesterol, or diabetes or participants who were previously diagnosed with hypertension (high blood pressure), high cholesterol, or diabetes					
VALUES AND	1 Yes	Participant v	Participant was prescribed medication for the condition			
DESCRIPTION (CODE FOR EACH CONDITION)	2 No	Participant v	Participant was not prescribed medication for the condition			
	5 Not Applicable ^a	never been of does not have measurement that she has	This question is not applicable for the patient because she has never been diagnosed with for the condition, either because she does not have for the condition (as assessed with a measurement at screening/ rescreening) or because she reports that she has never been diagnosed with for the condition (as assessed with self-report at screening/ rescreening).			
	7 Don't know/Not sure	medication f	Participant does not know whether she was prescribed medication for the condition This value will be flagged as a quality check			
	8 Don't want to answer	ra Participant d medication f	Participant does not want to answer whether she was prescribed medication for the condition			
	O No anguar recorded		This value will be flagged as a quality check			
	9 No answer recorded		No answer recorded This value will be flagged as an error			
ANALYSIS AND USE	To understand the cardiovascular disease risk factors of individual participants and the overall WISEWOMAN population					
	To assess the number of cases of hypertension, high cholesterol, and diabetes that have been previously diagnosed as opposed to newly detected cases among the WISEWOMAN population To assess the control and management of blood pressure, cholesterol, and diabetes among participants who have hypertension, high cholesterol, or diabetes					
	To assist in assessment of adherence to medication for hypertension, high cholesterol, and diabetes					
	To provide data element required to determine participant's ASCVD risk					
OTHER INFORMATION	^a Codes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only.					
	Each of the four positions in the Meds field corresponds to use of a condition-specific type of medication. The first position aligns with use of blood pressure medication. The second position aligns with use of statins for high cholesterol. The third position aligns with use of other medication (besides statins) for high cholesterol. The fourth position aligns with use of medication for diabetes.					

OTHER INFORMATION (CONT.)

Programs should assess a participant's prescribed medication status for each condition and record the corresponding value in the appropriate position in the Meds field. For example, if a participant reports that she: (a) has hypertension and is not prescribed blood pressure medication, (b) does not have high cholesterol and was not prescribed statins, (c) does not have high cholesterol and was not prescribed other cholesterol medication, and (d) has diabetes and was prescribed blood sugar medication, Meds should be recorded as '2551' (corresponding to values of '2 – No' in position 1, '5 – Not applicable' in position 2, '5 – Not applicable' in position 3, and '1 – Yes' in position 4).

If a participant reports that she doesn't know whether she was prescribed medication for one of these conditions or doesn't want to answer whether she was prescribed medication for one of these conditions, programs should have a discussion with her to verify the response.

Medication prescription status at screening is required for a record to count as a complete or BP+ record. If Meds is blank or coded as "9 No answer recorded," the record will not count as a complete or BP+ record, which means the record will not count toward meeting a program's screening goal.

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item Length: 1 Beginning Position: 77	Item 5b: Aspirin*	Are you taking aspirin daily to help prevent a heart attack or stroke? This variable indicates whether the participant is taking aspirin daily to help prevent a heart attack or stroke.				
Field Length: 1 Leading Zeros: No Valid Range: See values; cannot be blank SOURCE American College of Cardiology DENOMINATOR POPULATION VALUES AND DESCRIPTION A Don't know/Not sure Participant is not taking aspirin daily to help prevent a heart attack or stroke Denominator includes all Wisewoman is not taking aspirin daily to help prevent a heart attack or stroke Denominator includes all wisewoman is taking aspirin daily to help prevent a heart attack or stroke No Participant is not taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check Denominator includes all wisewoman is taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check Denominator includes in taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check Denominator includes in taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check Denominator includes in taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check No answer recorded This value will be flagged as an error ANALYSIS AND USE To understand the cardiovascular disease risk factors of individual participants and the overall WISEWOMAN population OTHER INFORMATION If a participant reports that she doesn't know whether she is taking aspirin or doesn't want to answer whether she is taking aspirin, programs should have a discussion with her to verify the response. Use of aspirin at screening is required for a record to count as a complete or BP+ record. If Aspirin is blank or coded as "9 No answer recorded,' the record will not count as a complete or	FORMAT	Type:	Num	eric Other Format:	N/A	
Leading Zeros: No Valid Range: See values; cannot be Static Field: No SOURCE American College of Cardiology		Item Length:	1	Justification:	Right	
SOURCE American College of Cardiology DENOMINATOR POPULATION The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening VALUES AND DESCRIPTION 1 Yes Participant is taking aspirin daily to help prevent a heart attack or stroke 2 No Participant is not taking aspirin daily to help prevent a heart attack or stroke 7 Don't know/Not sure Participant does not know whether she is taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check 9 No answer recorded No answer recorded This value will be flagged as an error ANALYSIS AND USE To understand the cardiovascular disease risk factors of individual participants and the overall WISEWOMAN population OTHER INFORMATION accodes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only. If a participant reports that she doesn't know whether she is taking aspirin or doesn't want to answer whether she is taking aspirin, programs should have a discussion with her to verify the response. Use of aspirin at screening is required for a record to count as a complete or BP+ record. If Aspirin is blank or coded as "9 No answer recorded," the record will not count as a complete or		Field Length:	1	Beginning Position:	77	
SOURCE American College of Cardiology The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening VALUES AND DESCRIPTION 1 Yes Participant is taking aspirin daily to help prevent a heart attack or stroke 2 No Participant is not taking aspirin daily to help prevent a heart attack or stroke 7 Don't know/Not sure Participant does not know whether she is taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check 8 Don't want to answer Participant does not want to answer whether she is taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check 9 No answer recorded This value will be flagged as an error ANALYSIS AND USE To understand the cardiovascular disease risk factors of individual participants and the overall WISEWOMAN population OTHER INFORMATION a Codes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only. If a participant reports that she doesn't know whether she is taking aspirin or doesn't want to answer whether she is taking aspirin, programs should have a discussion with her to verify the response. Use of aspirin at screening is required for a record to count as a complete or BP+ record. If Aspirin is blank or coded as "9 No answer recorded,' the record will not count as a complete or		Leading Zeros:	No	Valid Range:	•	
DENOMINATOR POPULATION The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening 1 Yes Participant is taking aspirin daily to help prevent a heart attack or stroke 2 No Participant is not taking aspirin daily to help prevent a heart attack or stroke 7 Don't know/Not sure Participant does not know whether she is taking aspirin daily to help prevent a heart attack or stroke 8 Don't want to answer Participant does not want to answer whether she is taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check Participant does not want to answer whether she is taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check No answer recorded This value will be flagged as an error ANALYSIS AND USE To understand the cardiovascular disease risk factors of individual participants and the overall WISEWOMAN population OTHER INFORMATION a Codes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only. If a participant reports that she doesn't know whether she is taking aspirin or doesn't want to answer whether she is taking aspirin, programs should have a discussion with her to verify the response. Use of aspirin at screening is required for a record to count as a complete or BP+ record. If Aspirin is blank or coded as '9 No answer recorded,' the record will not count as a complete or		Static Field:	No		blank	
POPULATION Screening 1 Yes Participant is taking aspirin daily to help prevent a heart attack or stroke 2 No Participant is not taking aspirin daily to help prevent a heart attack or stroke 7 Don't know/Not sure Participant does not know whether she is taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check Participant does not want to answer whether she is taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check Participant does not want to answer whether she is taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check No answer recorded This value will be flagged as an error ANALYSIS AND USE To understand the cardiovascular disease risk factors of individual participants and the overall WISEWOMAN population OTHER INFORMATION a Codes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only. If a participant reports that she doesn't know whether she is taking aspirin or doesn't want to answer whether she is taking aspirin, programs should have a discussion with her to verify the response. Use of aspirin at screening is required for a record to count as a complete or BP+ record. If Aspirin is blank or coded as "9 No answer recorded," the record will not count as a complete or	SOURCE	American College of C	Cardiolo	gy		
DESCRIPTION stroke 2 No Participant is not taking aspirin daily to help prevent a heart attack or stroke 7 Don't know/Not sure Participant does not know whether she is taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check B Don't want to answer ^a Participant does not want to answer whether she is taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check No answer recorded This value will be flagged as an error ANALYSIS AND USE To understand the cardiovascular disease risk factors of individual participants and the overall WISEWOMAN population OTHER INFORMATION a Codes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only. If a participant reports that she doesn't know whether she is taking aspirin or doesn't want to answer whether she is taking aspirin, programs should have a discussion with her to verify the response. Use of aspirin at screening is required for a record to count as a complete or BP+ record. If Aspirin is blank or coded as "9 No answer recorded,' the record will not count as a complete or	DENOMINATOR POPULATION	·······································				
This value will be flagged as a quality check Participant does not know whether she is taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check Participant does not want to answer whether she is taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check No answer recorded This value will be flagged as an error To understand the cardiovascular disease risk factors of individual participants and the overall WISEWOMAN population OTHER INFORMATION aCodes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only. If a participant reports that she doesn't know whether she is taking aspirin or doesn't want to answer whether she is taking aspirin, programs should have a discussion with her to verify the response. Use of aspirin at screening is required for a record to count as a complete or BP+ record. If Aspirin is blank or coded as "9 No answer recorded,' the record will not count as a complete or	VALUES AND DESCRIPTION	· and part to taking deprine daily to help provent a me				
help prevent a heart attack or stroke This value will be flagged as a quality check 8 Don't want to answer Participant does not want to answer whether she is taking aspirin daily to help prevent a heart attack or stroke This value will be flagged as a quality check 9 No answer recorded No answer recorded This value will be flagged as an error ANALYSIS AND USE To understand the cardiovascular disease risk factors of individual participants and the overall WISEWOMAN population OTHER INFORMATION aCodes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only. If a participant reports that she doesn't know whether she is taking aspirin or doesn't want to answer whether she is taking aspirin, programs should have a discussion with her to verify the response. Use of aspirin at screening is required for a record to count as a complete or BP+ record. If Aspirin is blank or coded as "9 No answer recorded,' the record will not count as a complete or		2 No				
daily to help prevent a heart attack or stroke This value will be flagged as a quality check 9 No answer recorded This value will be flagged as an error ANALYSIS AND USE To understand the cardiovascular disease risk factors of individual participants and the overall WISEWOMAN population OTHER INFORMATION aCodes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only. If a participant reports that she doesn't know whether she is taking aspirin or doesn't want to answer whether she is taking aspirin, programs should have a discussion with her to verify the response. Use of aspirin at screening is required for a record to count as a complete or BP+ record. If Aspirin is blank or coded as "9 No answer recorded," the record will not count as a complete or		7 Don't know/Not sure		help prevent a heart attack or stroke		
This value will be flagged as an error ANALYSIS AND USE To understand the cardiovascular disease risk factors of individual participants and the overall WISEWOMAN population OTHER INFORMATION aCodes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only. If a participant reports that she doesn't know whether she is taking aspirin or doesn't want to answer whether she is taking aspirin, programs should have a discussion with her to verify the response. Use of aspirin at screening is required for a record to count as a complete or BP+ record. If Aspirin is blank or coded as "9 No answer recorded," the record will not count as a complete or		8 Don't want to answer ^a		daily to help prevent a heart attack or stroke		
WISEWOMAN population a Codes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only. If a participant reports that she doesn't know whether she is taking aspirin or doesn't want to answer whether she is taking aspirin, programs should have a discussion with her to verify the response. Use of aspirin at screening is required for a record to count as a complete or BP+ record. If Aspirin is blank or coded as "9 No answer recorded," the record will not count as a complete or		9 No answer recorded ^a				
INFORMATION presented to participants. They are provided for funded program use only. If a participant reports that she doesn't know whether she is taking aspirin or doesn't want to answer whether she is taking aspirin, programs should have a discussion with her to verify the response. Use of aspirin at screening is required for a record to count as a complete or BP+ record. If Aspirin is blank or coded as "9 No answer recorded,' the record will not count as a complete or	ANALYSIS AND USE					
answer whether she is taking aspirin, programs should have a discussion with her to verify the response. Use of aspirin at screening is required for a record to count as a complete or BP+ record. If Aspirin is blank or coded as "9 No answer recorded," the record will not count as a complete or	OTHER INFORMATION					
Aspirin is blank or coded as "9 No answer recorded," the record will not count as a complete or		answer whether she is taking aspirin, programs should have a discussion with her to verify the				
		Aspirin is blank or coded as "9 No answer recorded," the record will not count as a complete or				

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 5c: MedAdhere*	During the past 7 days, how many days did you take prescribed medication for the following conditions:					
	i. High blood pr	essu	re (0 - 7 days)			
	ii. High choleste	•	• •			
	iii. High blood su	_	• • •			
	This variable indicates the number of days out of the past 7 days, including the day of the screening, that the participant took prescribed medication to lower her blood pressure, cholesterol, and/or blood sugar.					
FORMAT	Type:		umeric	Other Format:	N/A	
	Item Length:			Justification:	Right	
	Field Length:	Field Length: 6		Beginning Position:	78	
	Leading Zeros:	ding Zeros: Ye		Valid Range:	See values; cannot be	
	Static Field:	Static Field: No			blank	
SOURCE	Adapted from National S	Surve	y of Children's	Health		
DENOMINATOR POPULATION	The denominator includes WISEWOMAN participants taking medication to lower blood pressure, cholesterol, or blood sugar					
VALUES AND DESCRIPTION	Number of days (01-07)		A numeric value indicating the number of days out of the past 7 days, including the day of the screening, that the participant took			
(CODE FOR EACH CONDITION)			prescribed medication for the condition Any value outside the valid range (01 – 07) will be considered an error			
	00 None		In the past 7 days, including the day of the screening, the participant did not take prescribed medication for the condition			
	55 Not Applicable ^a		This question is not applicable for the patient because she has never been diagnosed with the condition (high blood pressure, high cholesterol, or high blood sugar) and/or has indicated that she does not take medication for the condition			
	77 Don't know/Not sure		Participant is not sure whether she took prescribed medication to lower her cholesterol during the past 7 days including the day of the screening This value will be flagged as a quality check			
	88 Don't want to answer ^a		Participant did not want to answer whether she took prescribed medication for the condition during the past 7 days, including the day of the screening			
			This value will be flagged as a quality check			
	99 No answer recorded ^a		No answer recorded This value will be flagged as an error			
ANALYSIS AND USE	To facilitate assessment of adherence to medication prescribed for high blood pressure, high cholesterol, and diabetes					
	To assist in determining management and control for high blood pressure, high cholesterol, and diabetes					
OTHER INFORMATION	^a Codes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only.					
	Each of the three positions in the MedAdhere field corresponds with the number of days taking medication for a specific condition in the past week. The first position aligns with the number of days taking medication for hypertension. The second position aligns with the number of days taking medication for high cholesterol. The third position aligns with the number of days taking medication for high blood sugar.					

OTHER INFORMATION (CONT.)

Programs should assess the number of days a participant took prescribed medication for each condition and record the corresponding value in the appropriate position of 5c: MedAdhere. For example, if a participant reports that she: (a) has never been diagnosed with hypertension and has not been prescribed blood pressure medication, (b) was prescribed medication for high cholesterol and takes medication 7 day per week, and (c) has diabetes and was prescribed medication for blood sugar, but does not take this medication ever, MedAdhere should be recorded as '550700' (corresponding to values of '55 – Not applicable' in position 1, '07 – 7 days per week' in position 2, and '00 – None' in position 3).

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 5d: Monitored	After being prescribed medication, on what date(s) did the participant have her blood pressure re-measured either by a healthcare provider, or with another community resource?					
		ssure medication,	lood pressure is re-measured fowhich is often related to titration			
FORMAT	Type:	Numeric	Other Format:	MMDDCCYY		
	Item Length:	8	Justification:	Right		
	Field Length:	24	Beginning Position:	84		
	Leading Zeros:	Yes	Valid Range:	Valid date		
	Static Field:	No				
SOURCE	WISEWOMAN-speci	fic optional variable	e for blood pressure follow-up			
DENOMINATOR POPULATION	The denominator include pressure	ludes all WISEWO	MAN participants taking medica	tion to lower blood		
VALUES AND DESCRIPTION	Monitoring Dates Valid date in MMDDCCYY format Date when blood pressure is re-measured by a health care provider or another community resource Example: September 10, 2018 = 09102018					
ANALYSIS AND USE	To assist in determin	ing management a	and control for high blood pressu	ire		
OTHER INFORMATION	recorded in 12b: SBF recorded in 12c: DBF	P (positions 4 throu P (positions 4 throu		re re-measurements are		
	recorded in 12c: DBP (positions 4 through 12), programs should document the date of the blood pressure re-measurement in the Monitored field. The position of the re-measurement date in Monitored should correspond with the position of the blood pressure re-measurement in SBP and DBP. For example, the first systolic blood pressure re-measurement should be entered in positions 4 through 6 of SBP, the first diastolic blood pressure re-measurement should be entered in positions 4 through 6 of DBP, and the date of the first blood pressure re-measurement should be recorded in positions 1 through 8 of Monitored. If another re-measurement is obtained after the screening date and prior to a subsequent follow-up screening or rescreening, the second systolic blood pressure re-measurement should be recorded in positions 7 through 9 of SBP, the second diastolic blood pressure re-measurement should be recorded in position 7 through 9 of DBP, and the re-measurement date associated with the second blood pressure re-measurement should be recorded in position 9 through 16 of Monitored. Programs can submit up to three blood pressure re-measurements and re-measurement dates. If one or more SBP re-measurements or DBP re-measurements are recorded then a date must accompany it in Monitored (MDE 5d).					

Item 6a: BPHome	•	wheth		-	librated sources? essure at home or using
FORMAT	Type:	Num	eric Other	r Format:	N/A
	Item Length:	1	Justin	fication:	Right
	Field Length:	1	Begir	nning Position:	108
	Leading Zeros:	No	Valid	Range:	See values; cannot be
	Static Field:	No			blank
SOURCE	HealthStyles Survey				
DENOMINATOR POPULATION	The denominator including diagnosed with hyperte			ts with high blood	d pressure or previously
VALUES AND DESCRIPTION	1 Yes		Participant reports the home or using other of		her blood pressure at s
	2 No – Was never told to measure her blood pressure		Participant reports that she does not measure her blood pressure at home or using other calibrated sources because she was never told she should measure her blood pressure		
	3 No – Doesn't know how to measure her blood pressure		Participant reports that she does not measure her blood pressure at home or using other calibrated sources because she does not know how to measure her blood pressure		
	4 No – Doesn't have equipment to measure her blood pressure		Participant reports that she does not measure her blood pressure at home or using other calibrated sources because she does not have access to the required equipment to measure her blood pressure		
	5 Not Applicable ^a				patient because she has on (high blood pressure)
	7 Don't know/Not sure/Other		Participant is not sure whether she measures her blood pour at home or using other calibrated sources or provides son reason for why she does not measure her blood pressure home (for example, participant chooses not to measure heat home) This value will be flagged as a quality check		
	8 Don't want to ans	swer ^a		ant to answer whe	ether she measures her calibrated sources
	9 No answer recorded ^a		No answer recorded This value will be flagged as an error		
ANALYSIS AND USE	To determine self-cont	trol and	management of hyper	tension (high blo	od pressure)
OTHER INFORMATION	^a Codes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only. Participants should select one response that is the best option.				
	Guidance on blood pressure self-monitoring is available in the Self-Measured Blood Pressure Monitoring Guide by Million Hearts (Centers for Disease Control and Prevention. Self-Measured Blood Pressure Monitoring: Action Steps for Public Health Practitioners. Atlanta, GA: Centers for Disease Control and Prevention, US Dept. of Health and Human Services; 2013.)				

Item 6b: BPFreq	How often do you measure your blood pressure at home or using other calibrated sources?						
	This variable indicates how frequently the participant measures her blood pressure at home or using other calibrated sources.						
FORMAT	Type:	Num	neric Other Format:	N/A			
	Item Length:	1	Justification:	Right			
	Field Length:	1	Beginning Position:	109			
	Leading Zeros:	No	Valid Range:	See values; cannot be			
	Static Field:	No		blank			
SOURCE	HealthStyles Survey						
DENOMINATOR POPULATION			/ISEWOMAN participants with high blood n (high blood pressure)	pressure or previously			
VALUES AND DESCRIPTION	1 Multiple times p	er day	Participant measures her blood pressur calibrated sources multiple times per da				
	2 Daily		Participant measures her blood pressure at home or using other calibrated sources once per day				
	3 A few times per week		Participant measures her blood pressure at home or using other calibrated sources a few times per week				
	4 Weekly 5 Monthly		Participant measures her blood pressure at home or using other calibrated sources once per week				
			Participant measures her blood pressure at home or using other calibrated sources once per month				
	6 Not Applicable ^a		This question is not applicable for the patient because she has never been diagnosed with hypertension (high blood pressure) or does not monitor her blood pressure at home or using other calibrated sources				
	7 Don't know/Not sure/Other		Participant is not sure how frequently she measures her blood pressure at home or using other calibrated sources This value will be flagged as a quality check				
	8 Don't want to ar	iswer ^a	Participant did not want to answer how frequently she measures her blood pressure at home or using other calibrated sources This value will be flagged as a quality check				
	9 No answer reco	rded ^a	No answer recorded				
			This value will be flagged as an error				
ANALYSIS AND USE			d management of hypertension (high bloo				
OTHER INFORMATION			is highlighted in gray should not appear or ney are provided for funded program use o				

Item 6c: BPSend	Do you regularly share blood pressure readings with a health care provider for feedback?							
	This variable indicates whether the participant shares blood pressure readings taken at home or using other calibrated sources with a health care provider for feedback almost every time she sees her provider.							
FORMAT	Type:	Num	eric Other Format:	N/A				
	Item Length:	1	Justification:	Right				
	Field Length:	1	Beginning Position:	110				
	Leading Zeros:	No	Valid Range:	See values; cannot be				
	Static Field:	No		blank				
SOURCE	Not applicable; WISE	EWOMA	N-specific variable					
DENOMINATOR POPULATION			ISEWOMAN participants with high bloc (high blood pressure)	d pressure or previously				
VALUES AND DESCRIPTION	1 Yes	Participant reports that she shares blood pressure readin at home or using other calibrated sources with a health caprovider for feedback almost every time she sees her pro						
	2 No		Participant reports that she does not readings taken at home or using othe health care provider for feedback					
	5 Not Applicable ^a		This question is not applicable for the never been diagnosed with hypertens does not monitor her blood pressure calibrated sources	sion (high blood pressure) or				
	7 Don't know/Not sure/Other		Participant is not sure whether she shares blood pressure readings taken at home or using other calibrated sources with a health care provider for feedback This value will be flagged as a quality check					
	8 Don't want to ar	iswer ^a	Participant did not want to answer who pressure readings taken at home or usources with a health care provider for	ether she shares blood sing other calibrated or feedback				
	0 N		This value will be flagged as a quality check					
	9 No answer reco	raeaª	No answer recorded This value will be flagged as an error					
ANALYSIS AND USE	To determine self-co	ntrol and		and pressure)				
MARION AND OOL	To determine self-control and management of hypertension (high blood press To determine whether blood pressure monitoring results are shared with a he- for monitoring of progress							
OTHER INFORMATION			s highlighted in gray should not appear ey are provided for funded program use					

Item 7a: FruitVeg*	How many cups of fruits and vegetables do you eat in an average day? This variable indicates the amount of fruit and vegetables the participant consumes in an average day.					
FORMAT	Type: Nume		eric	Other Format:	N/A	
	Item Length:	2		Justification:	Right	
	Field Length:	2		Beginning Position:	111	
	Leading Zeros:	Yes		Valid Range:	01-65; cannot be blank	
	Static Field:	No				
SOURCE	American Heart Asso	ciation				
DENOMINATOR POPULATION	The denominator incl screening	udes all	I WISEWOMA	N participants with a Comp	lete/BP+ baseline	
VALUES AND DESCRIPTION	Number of cups Two-digit (numeric) value representing the number of cups of f and vegetables the participant consumes in an average day				es in an average day	
			Any value o error	outside the valid range (01 -6	65) will be considered an	
			Example: 2 cups = 02			
	00 None		Participant does not consume fruit or vegetables in an average day			
	88 Don't want to an	swer ^a	Participant does not want to answer how many cups of fruit and vegetables she consumes in an average day			
			This value	vill be flagged as a quality c	heck	
	99 No answer recor	'ded ^a	No answer			
ANALYSIS AND USE	To determine the hea		naviors and C	vill be flagged as an error VD risk factors of individual	participants and the	
	To provide data elem	ents red	quired to dete	rmine participant's cardiova	scular risk	
OTHER INFORMATION				in gray should not appear or ed for funded program use o		
	Examples of one cup Life's Simple Seven p			es sourced from the America F.	an Heart Association's	
	complete record. If Fi	ruitVeg i	is blank, code	at screening is required for a rd as "99 No answer recorde t as a complete record.		

^{*}Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 7b: Fish*	Do you eat fish at least two times a week? This variable indicates whether the participant consumes two servings or more of fish weekly						
FORMAT	Type: Nun		meric	Other Format:	N/A		
	Item Length:	1		Justification:	Right		
	Field Length:	1		Beginning Position:	113		
	Leading Zeros:	No		Valid Range:	See values; cannot be		
	Static Field:	No			blank		
SOURCE	American Heart Ass	ociation	١				
DENOMINATOR POPULATION	The denominator in screening	cludes a	all WISEWO	MAN participants with a Comp	lete/BP+ baseline		
VALUES AND	1 Yes		Participant consumes two servings or more of fish weekly				
DESCRIPTION	2 No		Participant does not consume two servings or more of fish weekly				
	8 Don't want to answer ^a		Participant does not want to answer whether she consumes two servings or more of fish weekly				
			This value will be flagged as a quality check				
	9 No answer recorded ^a						
			This value	will be flagged as an error			
ANALYSIS AND USE	To determine the he overall WISEWOMA			d CVD risk factors of individual	participants and the		
	To provide data eler	ments re	equired to de	etermine participant's cardiova	scular risk		
OTHER INFORMATION				ed in gray should not appear or vided for funded program use o			
	•	Examples of servings of fish sourced from the American Heart Association's Life's Simple Seven provided in Appendix F.					
	•	•	•	is required for a record to cour recorded,' the record will not o	•		

^{*}Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 7c: Grains*	Thinking about all the servings of grain products you eat in a typical day, how many are whole grains?							
		This variable indicates the relative amount of whole grains the participant consumes compared to the total amount of grains consumed in a typical day.						
FORMAT	Type: Nume		eric Other Format:	N/A				
	Item Length:	1	Justification:	Right				
	Field Length:	1	Beginning Position:	114				
	Leading Zeros:	No	Valid Range:	See values; cannot be				
	Static Field:	No		blank				
SOURCE	United States Depart	ment of	Agriculture					
DENOMINATOR POPULATION	The denominator incl screening	udes all	WISEWOMAN participants with a Comp	olete/BP+ baseline				
VALUES AND DESCRIPTION	1 Less than half Less than half of servings of grain products consumed in day are whole grains 2 About half About half of servings of grain products consumed in a ty day are whole grains							
	3 More than half		More than half of servings of grain products consumed in a typical day are whole grains					
	8 Don't want to an	swer ^a	Participant does not want to answer ho products consumed in a typical day are This value will be flagged as a quality of	e whole grains				
	9 No answer recor	'ded ^a	No answer recorded This value will be flagged as an error					
ANALYSIS AND USE	To determine the healthy behaviors and CVD risk factors of individual participants and the overall WISEWOMAN population To provide data elements required to determine participant's cardiovascular risk							
OTHER INFORMATION			s highlighted in gray should not appear o ey are provided for funded program use					
	Examples of servings Simple Seven provide		le grains sourced from the American Heappendix F.	art Association's Life's				
			option at screening is required for a recorced as "9 No answer recorded," the recorded.					

^{*}Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 7d: Sugar*	Do you drink less than 36 ounces (450 calories) of sugar sweetened beverages weekly?					
	This variable indicat sugar sweetened be		er the participant drinks less than 36 oun weekly.	ices (450 calories) of		
FORMAT	Type:	Num	eric Other Format:	N/A		
	Item Length:	1	Justification:	Right		
	Field Length:	1	Beginning Position:	115		
	Leading Zeros:	No	Valid Range:	See values; cannot be		
	Static Field:	No		blank		
SOURCE	American Heart Ass	ociation				
DENOMINATOR POPULATION	The denominator incorrections	cludes al	WISEWOMAN participants with a Comp	lete/BP+ baseline		
VALUES AND DESCRIPTION	1 Yes		Participant consumes <i>less than</i> 36 ounces (450 calories) of beverages with added sugars in an average week			
	2 No		Participant consumes 36 ounces or <i>more</i> (450 calories or <i>more</i>) of beverages with added sugars in an average week			
	8 Don't want to answer ^a		Participant does not want to answer whether she consumes <i>less than</i> 36 ounces (450 calories) or more of beverages with added sugars in an average week This value will be flagged as a quality check			
	9 No answer recorded ^a		No answer recorded			
			This value will be flagged as an error			
ANALYSIS AND USE	To determine the he overall WISEWOMA		naviors and CVD risk factors of individual ation	participants and the		
	To provide data eler	ments red	quired to determine participant's cardiova	scular risk		
OTHER INFORMATION			s highlighted in gray should not appear o ey are provided for funded program use o			
	Examples of 36 ounces of beverages with added sugars sourced from the American Heart Association's Life's Simple Seven provided in Appendix F.					
		d. If Suga	everage consumption at screening is requar is blank or coded as "9 No answer reco			

^{*}Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 7e: SaltWatch*	Are you currently watching or reducing your sodium or salt intake? This variable indicates whether the participant is currently watching or reducing her sodium or salt intake.					
FORMAT	Type: Nume		eric Other Format:		N/A	
	Item Length:	1		Justification:	Right	
	Field Length:	1		Beginning Position:	116	
	Leading Zeros:	No		Valid Range:	See values; cannot be	
	Static Field:	No			blank	
SOURCE	CDC Behavioral Ris	k Factor	Surveillance S	System		
DENOMINATOR POPULATION	The denominator incorrection	cludes all	WISEWOMAI	N participants with a Comp	lete/BP+ baseline	
VALUES AND DESCRIPTION	1 Yes Participant is currently watching or reducing her sodiu intake				ucing her sodium or salt	
	2 No		Participant is not currently watching or reducing her sodium or salt intake			
	8 Don't want to a	nswer ^a		oes not want to answer wh reducing her sodium or sal		
			This value w	ill be flagged as a quality c	heck	
	9 No answer reco	orded ^a	No answer re	ecorded		
			This value w	ill be flagged as an error		
ANALYSIS AND USE	To determine the healthy behaviors and CVD risk factors of individual participants and the overall WISEWOMAN population					
OTHER INFORMATION	^a Codes and response options highlighted in gray should not appear on the data collection fo presented to participants. They are provided for funded program use only.					
	Whether a participant is watching her sodium intake at screening is required for a record to count as a complete record. If Saltwatch is blank or coded as "9 No answer recorded," the record will not count as a complete record.					

^{*}Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 7f: AlcFreq	In the past 7 days, how often do you have a drink containing alcohol? This variable indicates the number of days during the past 7 days that a participant had a drink containing alcohol.					
FORMAT	Type:	Numeric	Other Format:	N/A		
	Item Length:	2	Justification:	Right		
	Field Length:	2	Beginning Position:	117		
	Leading Zeros:	Yes	Valid Range:	See values; cannot be		
	Static Field:	No		blank		
SOURCE	Alcohol Use Disorder	s Identification Tes	st			
DENOMINATOR POPULATION	The denominator incl screening	udes all WISEWO	MAN participants with a Comple	te/BP+ baseline		
VALUES AND DESCRIPTION	Number of days	g the number of days int consumed a drink that e valid range (00-07) will				
	00 None		Participant has not consumed any drinks containing alcohol during the past 7 days			
	88 Don't want to an	past 7 c	Participant does not want to answer how many days during the past 7 days she has consumed drinks containing alcohol This value will be flagged as a quality check			
	99 No answer recor		No answer recorded This value will be flagged as a quality check			
ANALYSIS AND USE	To determine the healthy behaviors and CVD risk factors of individual participants and the overall WISEWOMAN population					
OTHER INFORMATION			ed in gray should not appear on t rided for funded program use on			

Item 7g: AlcDay	How many alcoholic drinks, on average, do you consume during a day you drink? This variable indicates the average number of alcoholic drinks consumed during a day.					
FORMAT	Type:	Numeric	Other Format:	N/A		
	Item Length:	2	Justification:	Right		
	Field Length:	2	Beginning Position:	119		
	Leading Zeros:	Yes	Valid Range:	See values; cannot		
	Static Field:	No		be blank		
SOURCE	Alcohol Use Disorde	rs Identificatio	n Test			
DENOMINATOR POPULATION	The denominator inc screening	ludes all WISI	EWOMAN participants with a Compl	ete/BP+ baseline		
VALUES AND DESCRIPTION	Number of drinks A numeric value indicating the average number of a drinks consumed during a day when the participant drinking alcohol					
			Any value outside the valid range (considered a quality check.	00 – 50) will be		
	00 None		The participant does not consume any alcoholic drinks			
	88 Don't want to ar	1swer ^a	Participant did not want to answer the average number of alcoholic drinks she consumes during a day when she is drinking alcohol			
			This value will be flagged as a qua	ity check		
	99 No answer reco	rded ^a	No answer recorded This value will be flagged as a qual	lity check		
ANALYSIS AND USE	To determine the heathe overall WISEWO		behaviors and CVD risk factors of interest of interest on	ndividual participants and		
OTHER INFORMATION			lighted in gray should not appear on e provided for funded program use o			
	(about 5% alcohol), (about 12% alcohol),	presented to participants. They are provided for funded program use only. A standard alcoholic drink is defined in Appendix F and as the follows: 12 fluid ounces of beer (about 5% alcohol), 8-9 fluid ounces of malt liquor (about 7% alcohol), 5 fluid ounces of wine (about 12% alcohol), or a 1.5 fluid ounce shot of 80 proof spirits (e.g., vodka, rum, gin, whiskey, tequila; about 40% alcohol).				

Item 8a: PA*		ites of physical activity (exercise) do you get in a week? cates the amount of physical activity the participant gets during an average					
FORMAT	Type:	Numeric	Other Format:	N/A			
	Item Length:	4	Justification:	Right			
	Field Length:	4	Beginning Position:	121			
	Leading Zeros:	Yes	Valid Range:	010-1700; cannot be			
	Static Field:	No		blank			
SOURCE	American Heart Assoc	ciation Life's					
DENOMINATOR POPULATION	The denominator inclusions	des all WISEWO	MAN participants with a Comp	lete/BP+ baseline			
VALUES AND DESCRIPTION	Number of minutes	activity the pa	umeric) value representing the irticipant gets during an averaç	ge week			
		Any value outside the valid range (0010 – 1700) will be considered a quality check					
		Example: 30 minutes = 0030					
		If the number of minutes of physical activity exceeds 1700 minutes of physical activity exceeds 1700 minutes of physical activity should be documented using the Validation of Data forn Appendix B for the procedure for validating out-of-range values					
	0000 None	Participant does not get any physical activity during an average w					
	8888 Don't want to answer ^a	Participant does not want to answer how much physical activity she gets during an average week					
		This value will be flagged as a quality check					
	9999 No answer recorded ^a	No answer recorded This value will be flagged as an error					
ANALYSIS AND USE	To determine the heal overall WISEWOMAN		I CVD risk factors of individual	participants and the			
	To provide data eleme	ents required to de	etermine participant's cardiova	scular risk			
OTHER INFORMATION	^a Codes and response options highlighted in gray should not appear on the data collection forms presented to participants. They are provided for funded program use only.						
	Examples of physical activity sourced from the American Heart Association's Life's Simple Seven provided in Appendix F.						
	Average physical activity at screening is required for a record to count as a complete record. If PA is blank or coded as "9999 No answer recorded,' the record will not count as a complete record.						

^{*}Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 9a: Smoker*	Do you smoke? Includes cigarettes, pipes, or cigars (smoked tobacco in any form) This variable indicates whether the participant smokes tobacco in any form, including cigarettes, pipes, or cigars.					
FORMAT	Type:		neric	Other Format:	N/A	
	Item Length:	1		Justification:	Right	
	Field Length:	1		Beginning Position:	125	
	Leading Zeros:	No		Valid Range:	See values; cannot be	
	Static Field:	No			blank	
SOURCE	American Heart Associ	ation				
DENOMINATOR POPULATION	The denominator include	des all \	WISEWOMA	N participants with a Complet	te/BP+ baseline screening	
VALUES AND DESCRIPTION	1 Current Smoker	Participant currently smokes tobacco in any form, including cigarettes, pipes, or cigars				
	2 Quit (1-12 months	t (1-12 months ago) Participant quit smoking tobacco in any form, including cigare pipes, or cigars, 1 to 12 months ago				
	3 Quit (More than 12 Participant quit smoking tobacco in any form, including cig pipes, or cigars, more than 12 months ago					
	4 Never Smoked			has never smoked tobacco in pipes, or cigars	any form, including	
	8 Don't want to answ	ver ^a				
	9 No answer recorde	ed ^a	No answer	recorded		
			This value	will be flagged as an error		
ANALYSIS AND USE	To determine the health WISEWOMAN populati		aviors and C	VD risk factors of individual pa	articipants and the overall	
			o might benefit from smoking cessation counseling and tobacco line and community-based)			
	To provide data elemer	nts requ	quired to determine participant's ASCVD risk			
OTHER INFORMATION				n gray should not appear on t ed for funded program use on		
	Smoker is blank or cod	ed as "	'9 No answe	r a record to count as a comp r recorded,' the record will not ot count toward meeting a pro	count as a complete or	

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 10a: PHQ*	Over the past 2 weeks, how often have you been bothered by any of the following problems? i. Little interest or pleasure in doing things (not at all, several days, more than half, or nearly every day)?						
	ii. Feeling down, depressed, or hopeless (not at all, several days, more than half, or nearly every day)?						
	This variable indicates the interest or pleasure in doin						
FORMAT	Type:	Numeric	Other Format:	N/A			
	Item Length: 2	2	Justification:	Right			
	Field Length: 2	2	Beginning Position:	126			
	Leading Zeros:	No	Valid Range:	See values; cannot be			
	Static Field:	No		blank			
SOURCE	Patient Health Questionna	ire (PHQ-2)					
DENOMINATOR POPULATION	The denominator includes	all WISEWOMAN	participants with a Comple	te/BP+ baseline screening			
VALUES AND DESCRIPTION	Not at all Participant has not been bothered by this issue at all over the two weeks						
(CODE FOR EACH ISSUE)	1 Several days	sue several days over the					
	2 More than half	s been bothered by this is past two weeks	sue more than half the				
	3 Nearly every day	Participant hat the past two v	is been bothered by this is veeks	sue nearly every day over			
	8 Don't want to answer	Participant do bothered by t	es not want to answer how his issue	v often she has been			
		This value wi	I be flagged as a quality ch	neck			
	9 No answer recorded ^a	No answer re					
411411/010 4115			I be flagged as an error				
ANALYSIS AND USE	To determine the health sta To provide health status in	•	•	• •			
OTHER INFORMATION	^a Codes and response option presented to participants.						
	Each of the two positions in the PHQ field corresponds with a different question. The first position aligns how often the participant reports having little interest in doing things. The second position aligns with how often the participant reports feeling down, depressed, or hopeless.						
	Programs should assess e appropriate position of 10a interest in doing things "se hopeless "more than half the (corresponding to values of this interest of this interest of the interest of t	i: PHQ. For examp veral days" in the pase ne days" in the pase f '1 – Several days	ole, if a participant reports to past two weeks and (b) has to two weeks, PHQ should by in position 1 and '2 – Mo	hat she: (a) has felt little s felt down, depressed, or be recorded as '12' re than half' in position 2).			

^{*}Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 11a: Height*	Height This variable in	dicates the p	participant's height in inches at ba	aseline screening.	
FORMAT	Type:	Numeric	Other Format:	N/A	
	Item Length:	2	Justification:	Right	
	Field Length:	2	Beginning Position:	128	
	Leading Zeros:	No	Valid Range:	48-76; cannot be blank if TYPE is 1, 2, 3 or 4 (baseline screening,	
	Static Field:	Yes		rescreening, or follow-up)	
SOURCE	American Hear	Association	1		
DENOMINATOR POPULATION	The denominate screening	or includes a	all WISEWOMAN participants with	h a Complete/BP+ baseline	
VALUES AND DESCRIPTION	Height in inches Up to a two-digit (numeric) value representing the p height at baseline screening			ue representing the participant's	
	Height values between 48" and 58" or 74" and 76" will be for quality checks and program verification. See Appendi the procedure for validating out-of-range values. Any value outside 48"-76" will be considered an error Example: 62" (5 feet, 2 inches) = 62				
	77 Unable to obtain Height measurement were not obtained. Se			mpted, but measurement results dix B for the procedure for ne measurement was not obtained n error	
	88 Client refus	ed ^a	Participant refuses to have her height measurement taken This value will be flagged as an error		
	99 No measur recorded ^a	ement	Height measurement was not performed This value will be flagged as an error		
ANALYSIS AND USE	To calculate the	BMI of WIS	SEWOMAN participants		
	To understand WISEWOMAN		scular disease risk factors of indi	vidual participants and the overall	
	To provide data	elements re	equired to determine participant's	cardiovascular risk	
OTHER INFORMATION	completed by the	^a Codes and response options highlighted in gray should not appear on the data collection forms completed by the provider. They are provided for funded program use only. All height measurements should be recorded in inches.			
*Ooreelete and DD:	If Height is blan measurement r as a complete of screening goal. should be docu	k or coded a ecorded,' or or BP+ recor If exception mented in th	as '777 Unable to obtain,' '888 Cl is outside of the valid range (48- d, and the record will not count to	76 inches) the record will not count oward meeting a program's ight measurement, these reasons ructed in Appendix B.	

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 11b: Weight*	Weight This variable ind	licates the	participant's weight in pounds.			
FORMAT	Type:	Numeri		N/A		
	Item Length:	3	Justification:	Right		
	Field Length:	3	Beginning Position:	130		
	Leading Zeros:	Yes	Valid Range:	074-460; cannot be blank if TYPE is 1, 2, 3 or 4 (baseline screening,		
	Static Field:	No		rescreening, or follow-up)		
SOURCE	American Heart	Associati	on			
DENOMINATOR POPULATION	The denominato screening	r includes	all WISEWOMAN participants w	ith a Complete/BP+ baseline		
VALUES AND DESCRIPTION	Weight in pounds Up to a three-digit (numeric) value representing the participal weight					
	Weight values between 74 and 90 lbs. or 350 and 460 lbs flagged for quality checks and program verification. See A for the procedure for validating out-of-range values. Any voutside 74-460 lbs. will be considered an error					
			Example: 98 lbs. = 098			
	777 Unable to	obtain	Weight measurement was attempted, but measurement results were not obtained			
				quality check. See Appendix B for the reason that the measurement was		
	888 Client refu	ısed ^a	Participant refuses to have her weight measurement taken			
			This value will be flagged as a c	quality check		
	999 No measu recorded ^a		Weight measurement was not p This value will be flagged as an			
ANALYSIS AND USE	To calculate the	BMI of W	ISEWOMAN participants			
	To understand to WISEWOMAN p		rascular disease risk factors of inc	dividual participants and the overall		
	To provide data	element r	equired to determine participant's	s cardiovascular risk		
OTHER INFORMATION				not appear on the data collection inded program use only.		
	record. If Weigh valid range (74- record will not c circumstances of	forms completed by the provider. They are provided for funded program use only. Weight measurement at screening is required for a record to count as a complete or BP+ record. If Weight is blank or coded as '999 No measurement recorded,' or is outside of the valid range (74-460 lbs.) the record will not count as a complete or BP+ record, and the record will not count toward meeting a program's screening goal. If exceptional circumstances do not allow weight measurement, these reasons should be documented in the Validation of Data form, as instructed in Appendix B.				

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 11c: Waist	Waist Circumference					
	This variable indicate	tes the pa	cipant's waist circumference i	n inches.		
FORMAT	Type:	Num	Other Format:	N/A		
	Item Length:	2	Justification:	Right		
	Field Length:	2	Beginning Pos	ition: 133		
	Leading Zeros:	No	Valid Range:	16-71		
	Static Field:	No				
SOURCE	American Heart Ass	ociation				
DENOMINATOR POPULATION	The denominator in screening	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening				
VALUES AND DESCRIPTION	Waist Circumference in inches		Up to a two-digit (numeric) value representing the participant's waist circumference in inches			
	Any value outside the valid range (16 – 71 incheas a quality check					
			ample: 30 inches = 30			
	77 Unable to obtai	n	aist circumference measuren easurement results were not	. ,		
	88 Client refused ^a		articipant refuses to have her ken	waist circumference measurement		
	99 No measureme recorded ^a	nt	aist circumference measuren	nent was not performed		
ANALYSIS AND USE	To understand the cardiovascular disease risk factors of individual participants and the overall WISEWOMAN population					
OTHER INFORMATION			ighlighted in gray should not are provided for funded pro	appear on the data collection forms gram use only.		

Item 12a: BPDate*	Clinical Assessment Date (Office Visit Date) This variable indicates the date of the office visit for a participant.						
FORMAT		Numeric	Other Format:	MMDDCCYY			
FORMAI	Type:						
	Item Length:	8	Justification:	Right			
	Field Length:	8	Beginning Position:	135			
	Leading Zeros:	Yes	Valid Range:	Valid date			
	Static Field:	No					
SOURCE	Not applicable; WISE\	NOMAN-specific vari	iable				
DENOMINATOR POPULATION	The denominator inclusive screening	ıdes all WISEWOMA	N participants with a Comp	olete/BP+ baseline			
VALUES AND	Clinical assessment	vana aato m	MMDDCCYY format				
DESCRIPTION	date/Office visit date	Date of the of	ffice visit for a participant				
		Example: Sep	otember 10, 2018 = 09102	018			
ANALYSIS AND USE	To identify the date of	the screening office	visit				
	To facilitate analysis of	of changes in blood p	ressure over time				
		•	luding time to rescreening,	, , ,			
	sessions, lifestyle prog sessions, alert referra		g follow-up screening, risk i	reduction counseling			
OTHER	Clinical assessment d	ate should be used to	o indicate the date that the	screening visit occurred.			
INFORMATION	If BPDate is missing or invalid, the record will not count as a complete or BP+ record, and the record will not count toward meeting a program's screening goal.						
	Since all screening measurements and assessments are to be used to determine part in the lifestyle programs and health coaching, it is expected that all labs and other so services will be completed within as short a time frame as possible. Thirty days is the recommended time frame in which blood pressure measurements should be done prefer the clinical assessment date unless specified by the program's medical advisory medical clinic.						

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 12b: SBP*	Systolic Blood P		uticing and a great list to the			
FORMAT		•	rticipant's systolic blood press Other Format:			
FURMAI	Type:	Numeric		N/A		
	Item Length:	3	Justification:	Right		
	Field Length:	12	Beginning Position:	143		
	Leading Zeros: Static Field:	Yes No	Valid Range:	074-260; cannot be blank if TYPE is 1, 2, 3 or 4 (baseline screening, rescreening or follow-up)		
SOURCE	Not applicable; he	alth screen	ing measurement	received mig of fellent up)		
DENOMINATOR POPULATION			WISEWOMAN participants wi	th a Complete/BP+ baseline		
VALUES AND DESCRIPTION	Systolic blood pr	ressure	A three-digit (numeric) value systolic blood pressure in mr	representing the participant's mHg		
(CODE FOR EACH READING AND IN THE ORDER TAKEN)	•		be flagged for quality checks	es between 230 and 260 mmHg will and program verification. Values e flagged as errors. See Appendix B ng out-of-range values		
			If a blood pressure measurement was not obtained at the time of the office visit and obtained at a referral visit within 30 days of the visit, the blood pressure measurement from the referral should be recorded here			
			Example: 90 mmHg = 090			
	777 Unable to o	btain	Systolic blood pressure measurement was attempted, but results were not obtained due to technical difficulties or errors			
			See Appendix B for the procedure for documenting the reason that the measurement could not be obtained			
			This value will be flagged as	an error		
	888 Client refus	ed ^a	Participant refuses to have her systolic blood pressure measurement taken			
			This value will be flagged as	an error		
	999 No measurement recorded ^a		Systolic blood pressure measurement was not performed or not recorded			
			This value will be flagged as an error			
ANALYSIS AND USE	To identify those a failure, stroke, and			ions, including heart attack, heart		
	To identify particip	ants who w	ould benefit from lifestyle prog	grams		
	To identify participants unaware that they have hypertension (high blood pressure) for referral to medical management					
	To determine control and management of blood pressure					
	To identify participants who require further diagnostic evaluation					
	To identify hypertension (high blood pressure) risk of the WISEWOMAN population					
	To provide data el	ement requ	ired to determine participant's	cardiovascular risk score		
OTHER INFORMATION	^a Codes and response options highlighted in gray should not appear on the data collection forms completed by the provider. They are provided for funded program use only.					
Programs can submit up to four systolic blood pressure measurements. (positions 1 through 3 of SBP) should correspond to the systolic blood pron the clinical assessment date. If more than one measurement is obtain assessment date, with a one minute interval as recommended by the Am Association, the average systolic blood pressure measurement should be 1 through 3.				stolic blood pressure measurement ment is obtained on the clinical ded by the American Heart		

OTHER INFORMATION (CONT.)

Programs may re-measure participants' systolic blood pressure prior to a subsequent follow-up screening or rescreening. If a program re-measures a participant's systolic blood pressure during follow-up, up to three additional systolic blood pressure measurements can be recorded in positions 4 through 6 (re-measurement #1), positions 7 through 9 (re-measurement #2), and positions 10 through 12 (re-measurement #3). Programs are not required to submit blood pressure re-measurements (positions 4 through 12); however, if blood pressure re-measurements are recorded, the date of re-measurement should be provided in 5d: Monitored. Systolic blood pressure measurement at screening (positions 1 through 3 of SBP) is required for a record to count as a complete or BP+ record. If positions 1 through 3 of SBP are blank or coded as '777 Unable to obtain,' '888 Client refused,' or '999 No measurement recorded,' or is outside of the valid range (74-260 mmHg) the record will not count as a complete or BP+ record, and the record will not count toward meeting a program's screening goal. If exceptional circumstances do not allow a blood pressure measurement during the clinical assessment (cases where positions 1 through 3 of SBP are coded as '777 Unable to obtain'), these reasons should be documented as instructed in Appendix B.

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 12c: DBP*	Diastolic Blood F				
FORMAT		· ·	articipant's diastolic blood pre	-	
FORMAT	Type:	Numeri		N/A	
	Item Length:	3	Justification:	Right	
	Field Length:	12	Beginning Position:	155	
	Leading Zeros: Static Field:	Yes No	Valid Range:	oo2-156; cannot be blank if TYPE is 1, 2, 3 or 4 (baseline screening,	
0011005	No. Comp. Production Inc.	- 101		rescreening or follow-up)	
SOURCE			ning measurement	The Occupation (BB) has all the	
DENOMINATOR POPULATION	screening	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening			
VALUES AND DESCRIPTION	Diastolic blood p in mmHg	ressure	diastolic blood pressure in m	•	
(CODE FOR EACH READING AND IN THE ORDER TAKEN)			mmHg will be flagged for qu Values outside 2-156 mmHg	ues between 2-12 mmHg or 122-156 ality checks and program verification. If will be considered errors. See be for validating out-of-range values	
			the office visit and obtained visit, the blood pressure mea recorded here		
	777 Unable to a		Example: 85 mmHg = 085		
	777 Unable to o	btain	Diastolic blood pressure measurement was attempted, but results were not obtained due to technical difficulties or errors		
			See Appendix B for the procedure for documenting the reason that the measurement could not be obtained		
			This value will be flagged as	an error	
	888 Client refus	ed ^a	Participant refuses to have her diastolic blood pressure measurement taken		
			This value will be flagged as an error		
	999 No measure recorded ^a	ement	Diastolic blood pressure measurement was not performed or not recorded		
			This value will be flagged as	an error	
ANALYSIS AND USE	To identify those a failure, stroke, and			litions, including heart attack, heart	
	To identify particip	ants who	would benefit from lifestyle pr	ograms	
	To identify particip medical managen		vare that they have hypertens	ion(high blood pressure) for referral to	
			anagement of blood pressure		
	• • •		require further diagnostic eva		
			gh blood pressure) risk of the		
OTHER	•		quired to determine participant		
OTHER INFORMATION			ոs highlighted in gray should r Гhey are provided for funded լ	not appear on the data collection forms program use only.	
	(positions 1 through on the clinical ass assessment date,	gh 3 of DB essment o with a one	P) should correspond to the date. If more than one measure minute interval as recommen	neasurements. The first measurement liastolic blood pressure measurement ement is obtained on the clinical nded by the American Heart ement should be recorded in positions	

OTHER INFORMATION (CONT.)

Programs may re-measure participants' diastolic blood pressure prior to a subsequent follow-up screening or rescreening. If a program re-measures a participant's diastolic blood pressure during follow-up, up to three additional diastolic blood pressure measurements can be recorded in positions 4 through 6 (re-measurement #1), positions 7 through 9 (re-measurement #2), and positions 10 through 12 (remeasurement #3). Programs are not required to submit blood pressure re-measurements (positions 4 through 12); however, if blood pressure re-measurements are recorded, the date of re-measurement should be provided in 5d: Monitored. Diastolic blood pressure measurement at screening (positions 1 through 3 of DBP) is required for a record to count as a complete or BP+ record. If positions 1 through 3 of DBP is blank or coded as '777 Unable to obtain,' '888 Client refused,' or '999 No measurement recorded,' or is outside of the valid range (2-156 mmHg) the record will not count as a complete or BP+ record, and the record will not count toward meeting a program's screening goal. If exceptional circumstances do not allow a blood pressure measurement (cases where first blood pressure measurement is coded as '777 Unable to obtain'), these reasons should be documented as instructed in Appendix B.

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 13a: Fast*	Fasting Status This variable indicates blood drawn for continuous	cates whe	ast nine hours prior to having		
FORMAT	Type:	Numeri	Other Format:	N/A	
	Item Length:	1	Justification:	Right	
	Field Length:	1	Beginning Position:	167	
	Leading Zeros:	No	Valid Range:	See values; cannot be blank if	
	Static Field:	No		TYPE is 1 or 2 (baseline screening or rescreening); cannot be blank if Type = 3 or 4 when any of the following are not blank: Totchol, HDL, LDL, Trigly, glucose	
SOURCE	Not applicable; he	ealth scre	ening measurement		
DENOMINATOR POPULATION	The denominator screening	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening			
VALUES AND DESCRIPTION	1 Yes Participant fasted for at least nine hours drawn			ne hours prior to having blood	
	2 No		Participant did not fast for at lea blood drawn	ast nine hours prior to having	
	9 No answer		No answer recorded		
	recorded ^a		Provider failed to confirm fastin available from the provider	g status or no information is	
			This value should be marked if LDL, 14d: Trigly, and 15a: Gluc 777/7777, or 888/8888		
		This value will be flagged as an error for baseline screer and rescreenings, and for follow-up screenings where lab was conducted			
ANALYSIS AND USE	To facilitate accurate identification of participants who have high cholesterol, borderline high cholesterol, diabetes, or pre-diabetes				
OTHER INFORMATION			ns highlighted in gray should no vider. They are provided for fund		
			she doesn't know or refuses bloo ant to verify the response.	od work, programs should have a	

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 14a: TotChol*	Total Cholesterol (fasting or nonfasting) This variable indicates the participant's total cholesterol level.					
FORMAT	Type:	Numei	· · · · · · · · · · · · · · · · · · ·	N/A		
	Item Length:	3	Justification:	Right		
	Field Length:	3	Beginning Position:	168		
	Leading Zeros:	Yes	Valid Range:	044-702; cannot be blank if		
	Static Field:	No	·	TYPE is 1 or 2 (baseline screening or rescreening)		
SOURCE	Not applicable; he	ealth scr	eening measurement			
DENOMINATOR POPULATION	The denominator screening	includes	s all WISEWOMAN participants with	a Complete/BP+ baseline		
VALUES AND DESCRIPTION	Total cholestero mg/dL	l in	A three-digit (numeric) value repre cholesterol in mg/dL	esenting the participant's total		
			Total cholesterol values that are between 44 and 60 mg/dL or 400 and 702 mg/dL will be flagged for quality checks and program verification. Values outside 44-702 will be considered errors. See Appendix B for the procedure for validating out-of-range values Example: 90 mg/dL = 090			
	777 Inadequate blood sample		Total cholesterol measurement was attempted, but results were not obtained due to technical difficulties or errors			
			This may include issues such as (attempts; (2) insufficient amount of invalid Cholestech readings due to submitted to laboratory, test not delaboratory request or other papers.	of blood, type of test tube; (3) o very high/low values; (4) sample one due to erroneous or missing		
			See Appendix B for the procedure for documenting the reason that the measurement was not obtained			
			This value will be flagged as an er	ror		
	888 Client refus	sed ^a	Participant refuses to have her blomeasurements	ood drawn for cholesterol		
			If the participant refuses to go to t considered to have refused	he lab, the participant can be		
			If the participant does not go to the follow-up has been attempted, the have refused	participant can be considered to		
			This value will be flagged as an e			
	999 No measure recorded ^a	ement	No total cholesterol measurement This value will be flagged as an er rescreenings			
ANALYSIS AND USE			no are unaware that they have high or referral to medical management	or borderline high cholesterol and		
			control and management			
	To assess the per borderline high ch		e of WISEWOMAN participants who have high cholesterol or			
			WISEWOMAN population for cardiovascular disease			
	Γο provide data e	lement r	required to determine participant's c	ardiovascular risk score		

^aCodes and response options highlighted in gray should not appear on the data collection forms completed by the provider. They are provided for funded program use only.

Total cholesterol measurement may be taken as fasting or nonfasting. At a minimum, every participant must have a total cholesterol, HDL cholesterol (14b: HDL), and LDL cholesterol (14c: LDL) value recorded.

Total cholesterol measurement at baseline screening or rescreening is required for a record to count as a complete or BP+ record. If TotChol is blank or coded as '777 Unable to obtain,' '888 Client refused, or '999 No measurement recorded,' or is outside of the valid range (044-702 mg/dL) the record will not count as a complete or BP+ record. If exceptional circumstances do not allow TotChol measurement, these reasons should be documented in the Validation of Data form as instructed in Appendix B.

Total cholesterol measurement may not be medically necessary at follow-up screening if a participant had normal cholesterol levels at baseline screening anchored in American Heart Association guidelines.

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 14b: HDL*	HDL Cholesterol This variable indic	-	g or nonfasting) participant's HDL cholesterol level.		
FORMAT	Type:	Nume	eric Other Format:	N/A	
	Item Length:	3	Justification:	Right	
	Field Length:	3	Beginning Position:	171	
	Leading Zeros:	Yes	Valid Range:	007-196; cannot be blank if	
	Static Field:	No		TYPE is 1 or 2 (baseline screening or rescreening)	
SOURCE	Not applicable; he	alth scr	eening measurement		
DENOMINATOR POPULATION	The denominator i screening	includes	all WISEWOMAN participants with a	Complete/BP+ baseline	
VALUES AND DESCRIPTION	HDL cholesterol mg/dL	in	A three-digit (numeric) value represe cholesterol in mg/dL	enting the participant's HDL	
	HDL cholesterol values flagged for quality chec			veen 155 and 196 mg/dL will be am verification. Values outside crors. See Appendix B for the values	
	777 Inadequate blood sample		HDL cholesterol measurement was attempted, but results were not obtained due to technical difficulties or errors		
			This may include issues such as (1) attempts; (2) insufficient amount of be invalid Cholestech readings due to visubmitted to laboratory, test not done laboratory request or other paperwood	blood, type of test tube; (3) ery high/low values;(4) sample e due to erroneous or missing	
			See Appendix B for the procedure for the measurement was not obtained	-	
			This value will be flagged as an error		
	888 Client refus	ed ^a	Participant refuses to have her blood measurements	d drawn for cholesterol	
			If the participant refuses to go to the considered to have refused	lab, the participant can be	
			If the participant does not go to the s follow-up has been attempted, the pa have refused		
			This value will be flagged as an erro	r	
	999 No measure	ement	No HDL cholesterol measurement was taken or recorded		
	recorded ^a		This value will be flagged as an error for baseline screenings and rescreenings		
ANALYSIS AND USE			o are unaware that they have low HD erral to medical management	L cholesterol and need	
	•	centage	of WISEWOMAN participants who ha	ave high cholesterol or	
		o assess the risk of the WISEWOMAN population for cardiovascular disease			
	To assist in determ	nining c	holesterol control and management		

^aCodes and response options highlighted in gray should not appear on the data collection forms completed by the provider. They are provided for funded program use only.

HDL cholesterol measurement may be taken as fasting or nonfasting. At a minimum, every participant must have a total cholesterol, HDL cholesterol (14b: HDL), and LDL cholesterol (14c: LDL) value recorded.

In cases where the Cholestech machine indicates a reading of less than 15 mg/dL, the guidance is to code the participant's HDL as 015.

HDL cholesterol measurement at baseline screening or rescreening is required for a record to count as a complete or BP+ record. If HDL is blank or coded as '777 Unable to obtain,' '888 Client refused, or '999 No measurement recorded,' or is outside of the valid range (007-196 mg/dL) the record will not count as a complete or BP+ record. If exceptional circumstances do not allow HDL measurement, these reasons should be documented in the Validation of Data form as instructed in Appendix B.

HDL cholesterol measurement may not be medically necessary at follow-up screening if a participant had normal cholesterol levels at baseline screening anchored in American Heart Association guidelines.

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 14c: LDL*	LDL Cholesterol This variable indic	-	g or nonfasting) participant's LDL cholesterol level		
FORMAT	Type:	Nume	ric Other Format:	N/A	
	Item Length:	3	Justification:	Right	
	Field Length:	3	Beginning Position:	174	
	Leading Zeros:	Yes	Valid Range:	020-380: cannot be blank if	
	Static Field:	No		TYPE is 1 or 2 (baseline screening or rescreening)	
SOURCE	2018 AHA/ACC G	Guideline	e on the Management of Blood Cholest	erol	
DENOMINATOR POPULATION	The denominator screening	include	s all WISEWOMAN participants with a 0	Complete/BP+ baseline	
VALUES AND DESCRIPTION	LDL cholesterol in mg/dL A three-digit (numeric) value representing a participant's L cholesterol in mg/dL				
		LDL cholesterol values that are between 344 and 380 n flagged for quality checks and program verification. LDL values that are outside 020 and 380 mg/dL will be cons See Appendix B for the procedure for validating out-of-r			
			For <i>nonfasting</i> participants who are on lipid-lowering therapy, have a nistory of high cholesterol, or have a triglyceride level >0400 mg/dL, any value in this field will be flagged for an error. See below for additional guidance		
			Example: 90 mg/dL = 090		
	777 Inadequate blood sample		LDL cholesterol measurement was attempted, but results were not obtained due to technical difficulties or errors		
			This may include issues such as (1) t attempts; (2) insufficient amount of bl invalid Cholestech readings due to ve submitted to laboratory, test not done laboratory request or other paperworl	ood, type of test tube; (3) ery high/low values; (4) sample due to erroneous or missing	
		This response should also be used for participants on lip therapy with a history of high cholesterol who were confir fasting, but their LDL cholesterol was unable to be obtain			
			This value will be flagged as an error		
	888 Client refus	888 Client refused ^a Participant refuses to receive a lipid panel that would inc measurements			
			This response should also be used for participants on therapy or with a history of high cholesterol who were be fasting, but refused a lipid panel		
			This value will be flagged as an error		
	999 No measure recorded ^a	ement	No LDL cholesterol measurement wa		
	recorded*		Nonfasting participants who are on lipid-lowering therapy, have a history of high cholesterol, or have a triglyceride level >0400 mg/dL should always have this value		
ANALYSIS AND USE	To assist in deter	mining c	cholesterol control and management		

^aCodes and response options highlighted in gray should not appear on the data collection forms completed by the provider. They are provided for funded program use only.

At a minimum, every participant must have a total cholesterol, HDL cholesterol (14b: HDL) and LDL cholesterol (14C: LDL) value recorded.

LDL cholesterol measurement at baseline screening or rescreening is required for a record to count as a complete or BP+ record. If LDL is blank or coded as '777 Unable to obtain,' '888 Client refused, or '999 No measurement recorded,' or is outside of the valid range (020-380 mg/dL) the record will not count as a complete or BP+ record. If exceptional circumstances do not allow LDL measurement, these reasons should be documented in the Validation of Data form as instructed in Appendix B.

LDL cholesterol measurement may not be medically necessary at follow-up screening if a participant had normal cholesterol levels at baseline screening based on American Heart Association guidelines.

As per the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol, measurement of either a fasting or a nonfasting plasma lipid profile is effective in estimating initial ASCVD risk if the participant is not on lipid-lowering therapy and does not have a history of high cholesterol.

Therefore, although assessing lipids when the participant is fasting may be more prudent, for participants not on lipid-lowering therapy and without a history of high cholesterol, LDL cholesterol may be measured for fasting or nonfasting participants. It is not recommended to measure nonfasting LDL if a participant has consumed an extremely high-fat meal 8 hours prior to blood work. In this case, blood work should be measured on another day (preferably fasting).

Additionally, for any participants with a family history of heart attacks or other atherosclerotic disease at an early age (< 50-55 years) or who have a genetic history of hyperlipidemia, it is reasonable to obtain an initial fasting lipid profile.

For participants on lipid-lowering therapy, or who have a history of high cholesterol, LDL cholesterol should be measured only when the participant is fasting. If a participant meets either of these criteria and is not fasting when cholesterol is initially measured, the provider may remeasure fasting cholesterol within 30 days of the office visit. In this case, the fasting status (13a: Fast), total cholesterol (14a:TotChol), HDL cholesterol (14b:HDL), LDL cholesterol (14c: LDL), and triglycerides (14d:trigly) values should also be updated in the screening record.

For participants who are not on lipid-lowering therapy and do not have a history of high cholesterol, but who were not fasting and had a triglyceride (14d: Trigly) level greater than or equal to 400 mg/dL, blood work should be performed again as a fasting measurement within 30 days of the initial screening. In this case, the fasting status (13a: Fast), total cholesterol (14a:TotChol), HDL cholesterol (14b:HDL), LDL cholesterol (14c: LDL), and triglycerides (14d:Trigly) values should also be updated in the screening record.

If an LDL measurement is recorded when the participant was not confirmed to be fasting, programs should check with providers to determine whether the participant actually was fasting.

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 14d: Trigly		Triglycerides (fasting or nonfasting) This variable indicates a participant's triglycerides measurement.					
FORMAT	Type:	Numer		N/A			
	Item Length:	4	Justification:	Right			
	Field Length:	4	Beginning Position:	177			
	Leading Zeros:	Yes	Valid Range:	0012-3000			
	Static Field:	No					
SOURCE	2018 AHA/ACC G	Guideline c	on the Management of Blood Cholester	ol			
DENOMINATOR POPULATION	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening						
VALUES AND DESCRIPTION	Triglycerides in mg/dL		A four-digit (numeric) value representing a participant's triglycerides measurement in mg/dL				
		;	For <i>fasting</i> participants, triglycerides values between 1,000 and 3,000 mg/dL will be flagged for quality checks and program verification. Values outside 0012-3000 mg/dL will be considered errors. See Appendix B for the procedure for validating out-of-range values				
		;	For <i>nonfasting</i> participants who are on lipid-lowering therapy or hav a history of high cholesterol, any value in this field will be flagged fo an error				
			For <i>nonfasting</i> participants who are NOT on a lipid-lowering therapy and do NOT have a history of high cholesterol, a triglycerides level outside 0012-0400 mg/dL will be flagged for an error. In this case, programs should repeat the lipid panel within 30 days to obtain the fasting values. See additional guidance below				
	Example: 90 mg/dL = 0090						
	7777 Inadequate blood sample		Triglycerides measurement was attempted, but results were not obtained due to technical difficulties or errors				
		; ;	This may include issues such as (1) two attempts; (2) insufficient amount of bloo invalid Cholestech readings due to very submitted to laboratory, test not done of laboratory request or other paperwork	od, type of test tube; (3) / high/low values; (4) sample			
		1	This response should also be used for therapy or with a history of high cholest be fasting, but their triglycerides measu	terol who were confirmed to			
	8888 Client refus		Fasting participant refuses to receive a triglycerides measurements	lipid panel that would include			
		1	This response should also be used for participants on lipid-lowering therapy or with a history of high cholesterol who were confirmed to be fasting, but refused a lipid panel				
	9999 No measurement recorded ^a		No triglycerides measurement was taken or recorded Nonfasting participants who are on lipid-lowering therapy or have a				
	recorded*						

^aCodes and response options highlighted in gray should not appear on the data collection forms completed by the provider. They are provided for funded program use only.

At a minimum, every participant must have a total cholesterol, HDL cholesterol (14b: HDL) and LDL cholesterol (14C: LDL). A triglyceride (14d: Trigly) value can also be recorded in addition to total cholesterol, HDL cholesterol, and LDL cholesterol. Triglycerides measurement may not be medically necessary at follow-up screening if a participant had normal cholesterol levels at baseline screening based on American Heart Association guidelines

As per the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol, measurement of either a fasting or a nonfasting plasma lipid profile is effective in estimating initial ASCVD risk if the participant is not on lipid-lowering therapy and does not have a history of high cholesterol.

Therefore, although assessing lipids when the participant is fasting may be more prudent, for participants not on lipid-lowering therapy and without a history of high cholesterol, triglycerides may be measured for fasting or nonfasting participants. It is not recommended to measure nonfasting triglycerides if a participant has consumed an extremely high-fat meal 8 hours prior to blood work. In this case, blood work should be measured on another day (preferably fasting). Additionally, for any participants with a family history of heart attacks or other atherosclerotic disease at an early age (< 50-55 years) or who have a genetic history of hyperlipidemia, it is reasonable to obtain an initial fasting lipid profile.

For participants on lipid-lowering therapy or with a history of high cholesterol, triglycerides should be measured only when the participant is fasting. If a participant is not fasting when cholesterol is initially measured, the provider may re-measure fasting cholesterol within 30 days of the office visit. In this case, the fasting status (13a: Fast), total cholesterol (14a:TotChol), HDL cholesterol (14b: HDL), LDL cholesterol (14c: LDL), and triglycerides (14d: Trigly) values should also be updated in the screening record.

For participants who are not on lipid-lowering therapy and do not have a history of high cholesterol, but who were not fasting and had a triglyceride level greater than or equal to 400 mg/dL, blood work should be performed again as a fasting measurement within 30 days of the initial screening. If a provider decides to re-measure the cholesterol within 30 days of the office visit so that the values are fasting, the fasting status (13a:Fast), total cholesterol (14a:TotChol), HDL cholesterol (14b:HDL), LDL cholesterol (14c: LDL), and triglycerides (14d:Trigly) values should also be updated in the screening record.

If a triglyceride measurement is recorded when the participant was not confirmed to be fasting, programs should check with providers to determine whether the participant actually was fasting.

Item 15a: Glucose*	Glucose (fasting) This variable indicates the participant's fasting glucose measurement.					
FORMAT	Type:	Numei		N/A		
	Item Length:	3	Justification:	Right		
	Field Length:	3	Beginning Position:	181		
	Leading Zeros:	Yes	Valid Range:	037-571; cannot be blank if A1C is		
	Static Field:	No	vana rango.	invalid and TYPE is 1 or 2 (baseline screening or rescreening)		
SOURCE	American Heart A	ssociati	on			
DENOMINATOR POPULATION	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening					
VALUES AND DESCRIPTION	Total glucose in mg/dL		Up to a three-digit (numeric) value representing the participant's fasting glucose level in mg/dL			
			Glucose values that are between 037 and 050 mg/dL or 275 and 571 mg/dL will be flagged for quality checks and program verification.			
			Values outside 037-571 will be considered errors. See Appendix B for the procedure for validating out-of-range values Example: 90 mg/dL = 090			
	777 Inadequate blood sample		Glucose measurement was attempted, but results were not obtained due to technical difficulties or errors			
			See Appendix B for the procedure for documenting the reason that the measurement was not obtained			
			This may include issues such as (1) two or more failed venipuncture attempts; (2) insufficient amount of blood, type of test tube; (3) invalid Cholestech readings due to very high/low values; (4) sample submitted to laboratory, test not done due to erroneous or missing laboratory request or other paperwork			
			This value will be flagged as an error if A1C is also invalid			
	888 Client refused ^a		Participant refuses to have her blood drawn for glucose measurements			
			If the participant refuses to go to the lab, the participant can be considered to have refused			
			If the participant does not go to the scheduled lab appointment after follow-up has been attempted, the participant can be considered to have refused			
			This value will be flagged as an error if A1C is also invalid			
	999 No measur	rement	No glucose measurement was taken for record			
	recorded ^a		Non-fasting participants should always have this value			
			This value will be flagged as an	error if A1C is also invalid		
ANALYSIS AND USE	To identify participants who have pre-diabetes and diabetes					
		To assist in determining diabetes control and management				
		To use blood glucose or A1C percentage to accurately assess a participant's diabetes status				
		To provide data element required to determine participant's cardiovascular risk To understand the overall rate of diabetes among the WISEWOMAN population				

^aCodes and response options highlighted in gray should not appear on the data collection form completed by the provider. They are provided for funded program use only.

Glucose must be a fasting measurement. Programs may record both a glucose and A1C measurement for a participant. Having values for both Glucose and A1C will not result in an error.

In cases where the Cholestech machine indicates a reading of less than 37 mg/dL, the guidance is to code the participant's glucose as 037. Such a reading can identify an imminent danger and requires urgent care.

A valid glucose measurement or A1C measurement at screening is required for a record to count as a complete record.

Values are considered invalid for the glucose variable if: (1) participant is fasting and glucose is left blank or coded as '777 Unable to obtain,' '888 Client refused, or '999 No measurement recorded, or is outside of the valid range (037-571 mg/dl), or (2) participant is not fasting.

Values are considered invalid for A1C variable if: (1) it is left blank, coded as '7777 Unable to obtain,' '8888 Client refused, or '9999 No measurement recorded,' or is outside of the valid range (02.8-16.2 mg/dL).

If exceptional circumstances do not allow Glucose measurement, these reasons should be documented in the Validation of Data form as instructed in Appendix B.

^{*}Complete require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 15b: A1C*	A1C Percentage This variable indic	cates the p	participant's A1C percentage ((if measured).		
FORMAT	Type:	Numerio	Other Format:	N/A		
	Item Length:	4	Justification:	Right		
	Field Length:	4	Beginning Position:	184		
	Leading Zeros:	Yes	Valid Range:	02.8-16.2; cannot be blank if		
	Static Field:	No		Glucose is blank and TYPE is 1 or 2 (baseline screening or rescreening)		
SOURCE	Not applicable; he	ealth scree	ening measurement			
DENOMINATOR POPULATION	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening					
VALUES AND DESCRIPTION	A1C percentage		Numeric value representing the participant's A1C percentage. A1C should be reported to one decimal point If A1C was measured by another provider within the last 3 months, it is acceptable to input the value if it is available			
						A1C values between 02.8% and 04.0% or 13.0% and 16.2% will be flagged for quality checks and program verification. Values outside 02.8%-16.2% will be considered errors. See Appendix B for the procedure for validating out-of-range values
			Example: 8.5% = 08.5 (where the decimal place counts as part of the variable length)			
			7777 Inadequate blood sample		A1C measurement was attempted, but results were not obtained due to technical difficulties or errors	
	This value will be flagged as an error if glucose is also invalid					
	8888 Client refused ^a		Participant refuses to have an A1C test			
			If a participant refuses to go to the lab, the participant can be considered to have refused			
			If a participant does not go to the scheduled lab appointment after follow-up has been attempted, the participant can be considered to have refused			
			This value will be flagged as an error if glucose is also invalid			
		9999 No measurement recorded ^a		No A1C measurement was taken or recorded		
	This value will be flagged as an error if glucose is also invalid					
ANALYSIS AND USE	To identify participants who have diabetes and refer them for medical management To identify participants who have higher-than-optimal A1C levels and would benefit from preventive services such as lifestyle programs To assist in determining diabetes control and management					
	To assess the cardiovascular disease risk factors in the WISEWOMAN population					
	To provide data element required to determine participant's cardiovascular risk score					
OTHER INFORMATION	^a Codes and response options highlighted in gray should not appear on the data collection forms completed by the provider. They are provided for funded program use only.					
INFORMATION	Participants with A1C percentage values greater than or equal to 6.5% are considered diabetic. Participants with A1C percentage values less than 6.5% but greater than or equal to 5.7% are considered pre-diabetic.					
	Programs may record both a glucose and A1C measurement for a participant. Having values for both Glucose and A1C will not result in an error.					
	A1C measurement or glucose measurement at screening is required for a record to be a complete record. If both Glucose and A1C are blank or coded as '777 Unable to obtain,' '888 Client refused, or '999 No measurement recorded, or are outside of the valid range (Glucose: 37-571 mg/dL; A1C: 2.8-16.2%), the record will not count as a complete record. If exceptional circumstances do not allow A1C measurement, these reasons should be documented in the Validation of Data form as instructed in Appendix B.					
	Note that WISEWOMAN does not designate an alert value for A1C, because the A1C value itself is a three-month average and is not accurate enough to identify that an individual's life is imminent danger and requires urgent care.					

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 16a: BPAlert	Is a medical follow-up for blood pressure reading necessary? This variable indicates whether medical follow-up for a participant's alert level blood pressure is medically necessary, as indicated by a SBP greater than 180 mmHg or DBP greater than 120 mmHg.					
FORMAT	Type: Numeric		Other Format:	N/A		
	Item Length:	1	Justification:	Right		
	Field Length:	1	Beginning Position:	188		
	Leading Zeros:	No	Valid Range:	See values; cannot be blank if		
	Static Field:	No		TYPE is 1, 2, 3 or 4 (baseline screening, rescreening or follow-up)		
SOURCE	JNC7 and American Heart Association 2017 guidelines					
DENOMINATOR POPULATION	Participants who have an alert level blood pressure value are included in the denominator					
VALUES AND	1 Medically necessary		Medical follow-up for blood pressure is medically necessary			
DESCRIPTION	2 Not medically needed		Medical follow-up for blood pressure is not medically necessary			
	Medically necessary follow- up appointment declined Client refused workup ^a		Medical follow-up for blood pressure is medically necessary but participant failed to attend follow-up appointment			
			Participant had an alert level blood pressure reading but refused workup			
	9 No answer re	corded ^a	No answer recorded. This value will be flagged as an error.			
ANALYSIS AND USE	To assess whether participants with alert level blood pressure readings are receiving a workup To assist in determining hypertension (high blood pressure) management, and control					
OTHER INFORMATION	^a Codes and response options highlighted in gray should not appear on the data collection forms completed by the provider. They are provided for funded program use only.					
	A participant is classified as having an alert blood pressure reading if her systolic blood pressure reading measured during the screening (12b: SBP, positions $1-3$) is greater than 180 mmHg or if her diastolic blood pressure reading at screening (12c: DBP, positions $1-3$)) is greater than 120 mmHg.					
	"3 Medically necessary follow-up appointment declined" should be used when a client had an alert value and was scheduled to follow-up with a medical provider in within 7 days, however, she did not show-up for the appointment					
	"8 Client refused workup" should be used when the client had an alert value, however, she refused to schedule a follow-up with a medical provider.					

Item 16b: BPDiDate	What is the date of the medically necessary follow-up appointment? This variable indicates the follow-up appointment date for a participant with an alert level blopressure reading.					
FORMAT	Type:	Numerio	Other Format:	MMDDCCYY		
	Item Length:	8	Justification:	Right		
	Field Length:	8	Beginning Position:	189		
	Leading Zeros:	Yes	Valid Range:	Valid date; cannot be blank if TYPE		
	Static Field:	No		is 1, 2, 3 or 4 (baseline screening, rescreening or follow-up)		
SOURCE	Not applicable; W	ISEWOM	N-specific variable			
DENOMINATOR POPULATION	Participants who I	nave an a	rt level blood pressure value	e are included in the denominator		
VALUES AND DESCRIPTION	Medically Necessary Follow-up Appointment Date Valid date in MMDDCCYY format If follow-up information is provided for this referral, the workup date can be entered Example: September 10, 2018 = 09102018					
ANALYSIS AND USE	To assess whether providers are performing timely workups for participants with alert level blood pressure values To determine whether programs are meeting the guideline of workups within one week of the screening for alert participants To assist in determining hypertension (high blood pressure) prevention, management, and					
OTHER INFORMATION	A participant is classified as having an alert blood pressure reading if her systolic blood pressure reading measured at the screening visit (12b: SBP, positions 1 - 3) is greater than 180 mmHg <i>or</i> if her diastolic blood pressure reading measured at the screening visit (12c: DBP, positions 1 - 3) is greater than 120 mmHg. Only participants who are coded as having an alert blood pressure reading (16a: BPAlert = '1 Medically necessary,' 3 Medically necessary – follow-up appointment declined,' 8 Client refused workup,' or '9 Workup not completed') should have a blood pressure diagnostic exam date. However, in cases where blood pressure readings are just under the alert threshold (SBPs > 165 and ≤ 180 and DBPs >110 and ≤ 120) a valid BPDiDate will result in a quality check rather than an error. If a participant with an alert blood pressure value has a blood pressure workup status (16a: BPAlert) coded as "1 Medically necessary,' this field must be completed with the date of the diagnostic exam. If a participant with an alert blood pressure value has a blood pressure workup status (16a: BPAlert) coded as '3- Medically necessary- follow-up appointment declined' or '8 Client refused workup,' this field should contain the date of refusal as defined by program protocol. If a participant with an alert blood pressure value has a blood pressure workup status (16a: BPAlert) coded as '9 Workup not completed,' this field should contain the date that the program					

4. RISK REDUCTION COUNSELING MDE SPECIFICATIONS

This section provides recipients with the information necessary to support collection and reporting of the Risk Reduction Counseling MDE, which must be done according to the specifications provided in this section of the manual. Risk reduction counseling should be provided at all screenings.⁴

For a record to be counted as a Complete screening, it must have valid values for required MDEs. **Definitions of complete screenings are provided in Appendix A.**

This section begins with a summary of the required variable (Subsection a) and then provides the technical specifications for the variable (Subsection b).

.

⁴ Values left blank are considered invalid values for risk reduction counseling completion date.

a. Summary of Risk Reduction Counseling MDEs

Item Number	Variable Name	Beginning Position	Variable Label	Туре
17a	RRCComplete	197	Risk reduction counseling completion date	Numeric

b. Risk Reduction Counseling MDE Specifications

Item 17a: RRCComplete*	Risk Reduction Counseling Completion Date This variable indicates the date that risk reduction counseling was completed.					
FORMAT	Type:	Numeric	Other Format:	MMDDCCYY		
	Item Length:	8	Justification:	Right		
	Field Length:	8	Beginning Position:	197		
	Leading Zeros:	Yes	Valid Range:	Valid date; cannot be blank if TYPE		
	Static Field:	No	3	is 1, 2, 3 or 4 (baseline screening, rescreening or follow-up)		
SOURCE	Not applicable; W	'ISEWOMAN-s	pecific variable			
DENOMINATOR POPULATION	The denominator screening	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening				
VALUES AND	Risk reduction of	Y format				
DESCRIPTION	follow-up date		Date must occur within the submission period			
			Example: September 10, 2018 = 09102018			
	88888888 Participant refused further program contact ^a		Participant refused further program contact			
			This value will be flagged as a quality check			
	99999999 Partici follow-up ^a	pant lost to	Provider made three attempts to follow-up with participant but participant lost to follow-up.			
			This value will be flagged as a quality check			
ANALYSIS AND USE	To determine the provided for all so		eleted risk reduction couns	seling session, which should be		
	To facilitate analy	sis of changes	in risk reduction counseling	ng provision over time		
OTHER	^a Codes and response options highlighted in gray should not appear on the data collection forms					
INFORMATION	completed by the provider. They are provided for funded program use only.					
	If risk reduction counseling is completed on the same date as the clinical assessment, the same date should be recorded for 12a: BPDate and 17a: RRCComplete.					
	If laboratory results are not available at the time of the screening visit to provide risk reduction counseling, this field should be used to indicate the date on which risk reduction counseling was completed.					
	If RRCComplete	is blank the rec	ord will not count as a cor	mplete record.		

^{*}Complete records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

5. HEALTHY BEHAVIOR SUPPORT SERVICES MDE SPECIFICATIONS

This section provides recipients with the information necessary to support collection and reporting of Lifestyle Program/Health Coaching MDEs as well as referrals to community-based tobacco cessation resources which must be done according to the specifications provided in this section of the manual.

For a record to be counted as a Complete or BP+ screening, it must have valid values for required MDEs. Definitions of complete and BP+ screenings are provided in Appendix A.

An LSP/HC contact is counted if the following MDE variables in a record have valid values: date of LSP/HC session, LSP/HC ID, and date of referral.⁵ Recipients may report LSP/HC data that do not meet these requirements, but they will not be counted as an LSP/HC session, analyzed in data reports generated by CDC, or counted in the related performance measure unless additional documentation is provided.

This section begins with a summary of the 7 required variables (Subsection a) and then provides the technical specifications for each variable (Subsection b).

WISEWOMAN MDE Manual Edition 18.3

⁵ If a valid date of an LSP/HC session is provided, values left blank for LSPHCID or that are not included on the current list of CDC-approved LSP/HC IDs, are considered invalid values. If the date of an LSP/HC session is blank then the LSP/HC contact will not be counted.

a. Summary of Healthy Behavior Support Services MDEs

Item Number	Variable Name	Beginning Position	Variable Label	Туре
18a	RefDate	205	Lifestyle Program (LSP) / Health Coaching (HC) referral date	Numeric
19a	LSPHCRec	221	Number of Lifestyle Program (LSP) / Health Coaching (HC) Sessions Received by the Participant Associated with the Current Screening	Numeric
19b	Intervention	223	Date of Lifestyle Program (LSP) / Health Coaching (HC) session)	Numeric
19c	LSPHCID	351	Lifestyle Program (LSP) / Health Coaching (HC) ID	Character
20a	TobResDate	511	Date of referral to Tobacco Cessation Resource	Numeric
20b	TobResType	535	Type of Tobacco Cessation Resource	Numeric
20c	TResComp	538	Tobacco Cessation activity completed	Numeric

b. Healthy Behavior Support Services MDE Specifications

Item 18a: RefDate*	Lifestyle Program (LSP) / Health Coaching (HC) Referral Date This variable indicates the date that a referral to a LSP/HC occurred.				
FORMAT	Type: Nume		eric	Other Format:	MMDDCCYY
	Item Length:	8		Justification:	Right
	Field Length:	16		Beginning Position:	205
	Leading Zeros:	Yes		Valid Range:	Valid date
	Static Field:	No			
SOURCE	Not applicable; WISE	WOMA	N-specific var	iable	
DENOMINATOR POPULATION	The denominator includes all WISEWOMAN participants with a Complete/BP+ baseline screening				
VALUES AND DESCRIPTION	Lifestyle Program/Health Coaching Referral Date		Valid date in MMDDCCYY format Date must occur within the submission period Example: September 10, 2018 = 09102018		
	888888888888888 refused to answer		Participant refused LSP/HC referral. This value will be flagged as a quality check.		
ANALYSIS AND USE	To determine the date of the referral to an LSP/HC To assist in determining whether the participant has received a referral to a LSP/HC To assist in determining the number of LSP/HC referrals per participant To facilitate analysis of changes in LSP/HC referrals over time				
OTHER INFORMATION	To calculate the number of LSP or HC referrals per participant, the number of LSP/HC referral dates is counted for each unique participant ID (3a: EncodeID). For each screening, up to two referral dates can be recorded in this field and the Refdate should be recorded in the order in which the referrals occurred. If a provider attempts to refer a participant to an LSP/HC but the participant refuses to be referred, a value of 88888888888888888888888888888888888				

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 19a: LSPHCRec*	Number of Lifestyle Program (LSP) / Health Coaching (HC) Sessions Received by the Participant Associated with the Current Screening							
		This variable indicates the number of LSP/HC sessions the participant has received during the current screening prior to a subsequent follow-up screening or rescreening.						
FORMAT	Type:	Numeric	Other Format:	N/A				
	Item Length:	2	Justification:	Right				
	Field Length:	2	Beginning Position:	221				
	Leading Zeros:	Yes	Valid Range:	Cannot be blank if				
	Static Field:	No		Refdate is valid				
SOURCE	Not applicable; WISE\	NOMAN-specific varial	ole					
DENOMINATOR POPULATION	The denominator incluscreening	ides all WISEWOMAN	participants with a Comple	te/BP+ baseline				
VALUES AND DESCRIPTION	Number of Sessions	Number of Sessions Value representing the number of LSP/HC sessions the participant has received associated with the current screening Example: 6 visits = 06						
ANALYSIS AND USE	To track the number o	f LSP/HC sessions tha	t the participant has receive	ed				
OTHER INFORMATION	The number of LSP and HC sessions the participant has received during the current screening (prior to a subsequent follow-up screening or rescreening) should be provided in this field. During the creation of the analytic file, CDC will check that the number of LSP/HC sessions received by the participant is equal to the number of unique LSP/HC dates provided during the cooperative agreement period. Sessions will not count unless the record also contains a valid LSP/HC referral date (18a: RefDate).							

^{*}Complete and BP+ records require a valid response for this item. Refer to Table A.2 in Appendix A for more information.

Item 19b: Intervention	_	Date of Lifestyle Program (LSP) / Health Coaching (HC) Session For LSP/HC records, this variable indicates the date that the LSP/HC session occurred.					
	For LSP/HC records						
FORMAT	Type: Nume		eric	Other Format:	MMDDCCYY		
	Item Length:	8		Justification:	Right		
	Field Length:	128		Beginning Position:	223		
	Leading Zeros:	Yes		Valid Range:	Valid date		
	Static Field:	No					
SOURCE	Not applicable; WIS	EWOM	AN-specific variable	le			
DENOMINATOR POPULATION	All LSP/HC sessions screening	s amon	g WISEWOMAN p	articipants with a Comple	ete/BP+ baseline		
VALUES AND	Lifestyle Program/Health Valid date in MMDDCCYY format						
DESCRIPTION	Coaching Session Date		te Date must occur within the submission period				
		Example: September 10, 2018 = 09102018					
ANALYSIS AND USE	To determine the da	te of the	e LSP/HC session				
	To assist in determine	ning wh	ether the participa	nt has received an LSP/F	HC session		
	To assist in calculati	ng the i	number of LSP/HC	sessions per participant			
	To assess whether p	participa	ants with risk facto	rs receive LSP/HC servic	es		
	To assess changes participants who do		profile between par	ticipants who participate	in the LSP/HC and		
OTHER INFORMATION	To calculate the nun dates is counted for			ns per participant, the nui D (3a: EncodeID).	mber of LSP/HC session		
	Programs can enter up to 16 LSP/HC intervention dates per screening. If additional are provided to a participant before a subsequent follow-up screening or recsreening sessions should be recorded in the Supplemental LSP/HC Session form, as descri Appendix B.						
	referral was made. F	or examention	mple, if a referral to dates should be re	d on the screening record to health coaching was ma corded on this record, un	ade during the baseline		

Item 19c: LSPHCID	Lifestyle Program (LSP) / Health Coaching (HC) ID This variable indicates which LSP/HC was used.						
FORMAT	Type: Character		Other Format:	N/A			
	Item Length:	10	Justification:	Left			
	Field Length:	160	Beginning Position:	351			
	Leading Zeros:	N/A	Valid Range:	Valid code for an LSP/HC;			
	Static Field:	No		cannot be blank if valid date provided for Intervention			
SOURCE	Not applicable; WIS	Not applicable; WISEWOMAN-specific variable					
DENOMINATOR POPULATION	All LSP/HC session screening	All LSP/HC sessions among WISEWOMAN participants with a Complete/BP+ baseline screening					
VALUES AND	Lifestyle Program ID Value representing the ID code of the LSP as assigned						
DESCRIPTION	Health Coaching ID Value representing the ID code of the HC as assigned						
ANALYSIS AND USE	To assess the number of WISEWOMAN participants who receive an LSP/HC session from each WISEWOMAN LSP/HC provider						
	To describe differences in participant demographics or other characteristics by LSP/HC provider						
	To identify the number	To identify the number of LSP/HC providers in a given geographic area					
OTHER INFORMATION	If the participant rec	eives an LSP or F	HC session, the LSP/HC ID	should be provided in this field.			

Item 20a: TobResDate	Date of Referral to Tobacco Cessation Resource					
	This variable indic	cates the	date that the referral to a tobacco cessa	tion resource occurred.		
FORMAT	Type:	Numeri	Other Format:	MMDDCCYY		
	Item Length:	8	Justification:	Right		
	Field Length:	24	Beginning Position:	511		
	Leading Zeros:	No	Valid Range:	Valid date; cannot be		
	Static Field:	No		blank if Smoker=1		
SOURCE	Not applicable; W	ISEWON	AN-specific variable			
DENOMINATOR POPULATION	WISEWOMAN pa as current smoke		with a Complete/BP+ baseline screening	g who identify themselves		
VALUES AND	Tobacco Cessat		Valid date in MMDDCCYY format			
DESCRIPTION	Resource Referr	Date must occur within the submission period				
-		2018				
		88888888888888888888888888888888888888				
ANALYSIS AND USE			referral to tobacco cessation resource of tobacco cessation resource			
OTHER INFORMATION			tobacco cessation resources referrals procedered to the referral dates is counted for each un			
	If a participant is referred to one or more tobacco cessation resources, the date of referral (Item 20a:TobResDate), type of resource the participant was referred to (Item 20b: TobResType), and completion status for the resource at the end of the current screening (Item 20c: TResComp) should be recorded for each referral. The positions for the type of resource and completion status of resource for each referral should align with the position of the date of referral. For example, if a participant receives two referrals during the screening period, the date of referral, type of resource, and completion status for the second referral should be provided in the second position for each item. If a provider attempts to refer a participant to tobacco cessation resource but the participant refuses to be referred, a value of 88888888888888888888888888888888888					

Item 20b: TobResType	•			esource of tobacco cessation resource the	at the participant was referred	
FORMAT	Ту	/pe:	Numeric	Other Format:	N/A	
	Ite	em Length:	1	Justification:	Right	
	Fi	eld Length:	3	Beginning Position:	535	
	Le	eading Zeros:	No	Valid Range:	See values; cannot be	
	St	atic Field:	No		blank if valid date provided for TobResDate	
SOURCE	No	ot applicable; WIS	SEWOMAN-s	pecific variable		
DENOMINATOR POPULATION	WISEWOMAN participants with a Complete/BP+ baseline screening who identify themselves as current smokers					
VALUES AND	1 Quit line			Participant was referred to a proactive tobacco quit line		
DESCRIPTION	2 Community-based tobacco program			Participant was referred to a community-based tobacco program		
	3 Other tobacco cessation resources		cessation	Participant was referred to other tobacco cessation resources		
	4 Internet-based tobacco program		tobacco	Participant was referred to an internet-based tobacco program		
	9	No answer rec	orded ^a	No answer was recorded		
				This value will be flagged as an error if a valid date is provided for TobResDate		
ANALYSIS AND USE	To	determine the n	umber of smo	okers that received a referral to to	obacco cessation resource	
	To determine how frequently different types of tobacco cessation resources within and across programs					
				at follow-up and rescreening of v sus those who were not	vomen who were linked to	
OTHER INFORMATION				ghlighted in gray should not appo . They are provided for funded p		

Item 20c: TResComp	Tobacco Cessation Activity Completed This variable indicates whether the participant completed tobacco cessation activity.				
FORMAT	Type: Numeric		Other Format:	N/A	
	Item Length:	1	Justification:	Right	
	Field Length:	3	Beginning Position:	538	
	Leading Zeros:	No	Valid Range:	See values; cannot be	
	Static Field:	No		blank if valid date provided for TobResDate	
SOURCE	Not applicable; WISE	WOMAN-speci	ific variable		
DENOMINATOR POPULATION	WISEWOMAN partic current smokers	ipants with a Co	omplete/BP+ baseline screening	who identify themselves as	
VALUES AND DESCRIPTION	1 Yes – Completed cessation activity		Participant completed tobacco cessation activity		
	2 No – Partially completed tobacco cessation activity		Participant partially completed tobacco cessation activity		
	3 No – Discontinu tobacco cessati when reached		Participant decided to discontinue from tobacco cessation counseling when contacted by the tobacco cessation resource		
	4 No – Could not i conduct tobacco activity		Participant could not be reached when contacted by the tobacco cessation resource		
	9 No answer reco	rded ^a	No answer was recorded		
			This value will be flagged as a provided for TobResDate	n error if a valid date is	
ANALYSIS AND USE	To determine the nur	nber of smoker	s that participated in tobacco ce	ssation activities	
	To compare the smoking status at follow-up and rescreening of women who were linked to tobacco cessation resources versus those who were not linked to tobacco cessation resources				
OTHER INFORMATION			ghted in gray should not appear provided for funded program us		
	the resource is unknown	own, TResCom	a tobacco cessation resource but p should be coded as 2 (No – Pardingly if the completion status I	artially completed tobacco	

APPENDIX A: SCREENING DEFINITIONS AND SUBMISSION GUIDANCE

This Appendix provides screening definitions and submission guidance for MDE files, including those related to format, procedures, and security. Submissions will not be processed if recipients fail to follow the guidelines provided below.

Data Submission Guidance

Recipients must submit data to CDC through the Data Management System 3.0. For additional guidance on data submission, refer to the Data Management System Quick Reference Guide, available on the WISEWOMAN Data Management System website.

a. Screening Definitions

Table A.1 provides an overview of WISEWOMAN screening definitions. For MDE 18.3, recipients should report each baseline screening, follow-up screening, and rescreening as a separate row in their data file for the reporting period. CDC will use unique participant identifier (EncodeID), month and year of birth (MYB), and state/tribal FIPS code (STFIPS) to identify each woman within the data, and the Type field and the clinical assessment date (BPDate) to determine whether each record represents a baseline screening, rescreening, or follow-up screening for that woman.

Table A.1. Screening Definitions

Туре	Description	Line Layout of Data
Baseline Screening	Initial participant screening; establishes starting point for WISEWOMAN program	First line
Follow-up Screening	Post healthy behavior support service (must occur 3 months and no later than 11 months after a participant's baseline screening or last rescreening and within 4 to 6 weeks after completion of the LSP/HC)	Second line
Re-screening	Subsequent screenings occurring 11-18 months after a participant's baseline screening or last rescreening	Third line

CDC will determine whether each submitted baseline screening, rescreening, and follow-up screening record will be counted as complete or blood pressure plus (BP+) using the criteria described below, and further detailed in Table A.2.

A complete record, at minimum, includes valid values for the following MDEs:1

- Administrative and Demographic items (1a-3f)
- Disease Status and Health History (4a-4b)
- Medication Use, Aspirin Use, and Medication Adherence (5a-5c)
- Nutrition (7a 7e) and Physical Activity (8a)
- Smoking Status (9a)
- Stress (10a)

¹ Invalid values are defined in Table A 2 b

¹ Invalid values are defined in Table A.2 below and in the Edits documentation, which is available in the Data Management System 3.0.

- Height (11a) / Weight (11b)
- Clinical Assessment Date (12a)
- Blood Pressure (12b-12c)
- Fasting Status (13a)*
- Cholesterol (14a-14c)*
- Blood Sugar (15a or 15b)*
- Risk Reduction Counseling (17a)
- LSP/HC Referral Date (18a)
- LSP/HC Received (count) (19a)

A **BP+ record**, at minimum, includes valid values for the following MDEs:

- Administrative and Demographic items (1a-3f)
- Disease Status and Health History (4a-4b)
- Medication Use, Aspirin Use, and Medication Adherence (5a-5c)
- Smoking Status (9a)
- Height (11a) / Weight (11b)
- Clinical Assessment Date (12a)
- Blood Pressure (12b-12c)
- Fasting Status (13a)*
- Cholesterol (14a-14c)*
- LSP/HC Referral Date (18a)
- LSP/HC Received (count) (19a)

b. Data Conventions

This section provides an overview of the data file format and layout for the MDEs. It defines data length and position and describes the types of MDE data. The data conventions described here represent the raw file format and layout of MDEs that recipients must follow when submitting data to the Data Management System 3.0 website.

- **Data Types.** There are several data types, including date, geographic, character, and numeric.
 - Dates have the format MMDDCCYY.
 - MM represents the month and has a range of 01–12; use leading zeros with months 01–09. If month is missing, month is blank (as indicated by a period [.] in each blank position).

^{*}Labs may not be medically required for certain participants at follow-up screening, therefore, will not be included in the definition of complete and BP+ at this type of visit.

- DD represents the day of the month and has a range of 01–31; use leading zeros with days 01–09. If day is missing, day is blank (as indicated by a period [.] in each blank position).
- CC represents the century and has a range of 19–20. If century is missing, century is blank (as indicated by a period [.] in each blank position).
- YY represents the year and has a range of 00–99; use leading zeros with years 00–09. If year is missing, year is blank (as indicated by a period [.] in each blank position).
- Geographic data elements are state/tribal FIPS code, ANSI county code, county of residence, and ZIP code of residence. These are character variables, and require leading zeros to fill the field length.
- Character data elements are composed of letters of the alphabet, numbers, and special characters. These are left-justified, and in cases where the value does not fill the entire field length, extra spaces in the length should be left blank (as indicated by a period [.] in each blank position). If there are no data for a given MDE, all positions should either be filled with a period [.] or left blank.
- Numeric data elements are composed of numbers, minus signs, and decimal points. Numeric data elements are right-justified. If numbers are expected to the right of the decimal, the number of decimal places required is indicated in the MDE specification. In cases where the value does not fill the entire field length, leading zeros should be used to fill the field length.
- *Item Length.* Item length represents the number of characters (i.e., letters of the alphabet, numbers, and special characters) for one entry of the item.
- **Field Length.** If the data element may be collected more than one time during the screening, such as Intervention which captures the date of an LSP or HC session, the field length will allow for multiple entries of this data element.
- **Static Field.** If the field is static, it should not be updated or modified after the first time the element is recorded. For example, month and year of birth is considered a static field because it is not expected that a participant's date of birth would change over time. However, blood pressure measurements are not static fields since it could change over time.
- **Beginning Position.** Position is the location in the record of a data element. The length and position of each data element are provided in the MDE specifications.

The table below summarized the position, item length, and field length for the MDE variables. Cells with an 'X" indicate that an MDE variable is required to be valid for either a baseline screening, rescreening, or follow-up screening to count as either complete record or BP+ record.

Table A.2. MDE Item Format and Invalid Values

Position	Item Number	MDE Name	Item Length	Field Length	Complete	BP+	Invalid Values (for required items)
1	1a	StFips	2	2	Х	Х	Blank or not an allowable value*
3	1b	HdANSI	5	5	Х	Х	Blank**
8	1c	EnrollSiteID	5	5	Х	Х	Blank**
13	1d	ScreenSiteID	10	10	Х	Х	Blank**
23	2a	TimePer	1	1	Х	Х	Blank, out of range, or not an allowable value* if the record is a baseline screening
24	2b	Nscreen	1	1	Х	Х	Blank
25	2c	Туре	1	1	Х	Х	Blank, coded as missing (9), or not an allowable value*
26	2d	Navigation	1	1	Х	Х	Blank or not an allowable value*
27	3a	EncodeID	15	15	Х	Х	Blank
42	3b	ResANSI	5	5	Х	Х	Blank**
47	3c	Zip	5	5	Х	Х	Blank, coded as missing (99999) or not a valid 5-digit zip code
52	3d	MYB	6	6	Х	Х	Blank
58	3e	Latino	1	1	Х	Х	Blank, coded as missing (9), or not an allowable value*
59	3f	Race1	1	1	X	Х	Blank, coded as missing (9), or not an allowable value* Exception: Values of missing (9) are permitted if the participant is Latino
60	3g	Race2	1	1			
61	3h	Education	1	1			
62	3i	Language	2	2			
64	4a	SRC	3	3	Х	Х	First, second, or third position blank, coded as missing (9), or not an allowable value*
67	4b	SRHA	6	6	Х	Х	First, second, third, fourth, fifth, or sixth position blank, coded as missing (9) or not an allowable value*
73	5a	Meds	4	4	Х	Х	First, second, third, or fourth position blank, coded as missing (9) or not an allowable value*
77	5b	Aspirin	1	1	Х	Х	Blank, coded as missing, or not an allowable value*
78	5c	MedAdhere	6	6	x	х	Any set of two positions blank, coded as missing (99), out or range (>07), incorrectly coded as not applicable (55) for participants who were prescribed medication, or incorrectly coded as 01 through 07 days for participants who were not prescribed medication
84	5d	Monitored	8	24			

Position	Item Number	MDE Name	Item Length	Field Length	Complete	BP+	Invalid Values (for required items)
108	6a	BPHome	1	1			
109	6b	BPFreq	1	1			
110	6c	BPSend	1	1			
111	7a	FruitVeg	2	2	Х		Blank, coded as missing (99), or out of range (>65)
113	7b	Fish	1	1	Х		Blank, coded as missing (9), or not an allowable value*
114	7c	Grains	1	1	Х		Blank, coded as missing (9), or not an allowable value*
115	7d	Sugar	1	1	Х		Blank, coded as missing (9), or not an allowable value*
116	7e	SaltWatch	1	1	Х		Blank, coded as missing (9), or not an allowable value*
117	7f	AlcFreq	2	2			
119	7g	AlcDay	2	2			
121	8a	PA	4	4	Х		Blank, coded as missing (9999)
125	9a	Smoker	1	1	Х	Х	Blank, coded as missing (9), or not an allowable value*
126	10a	PHQ	2	2	Х		First or second position is blank, coded as missing (9), or not an allowable value*
128	11a	Height	2	2	Х	Х	Blank or coded as unable to obtain (77), refused (88), missing (99), or out of range (<48; >76)
130	11b	Weight	3	3	Х	Х	Blank, coded as missing (999), or out of range (<74; >460)
133	11c	Waist	2	2			
135	12a	BPDate	8	8	Х	Х	Blank or illogical entry (e.g., date is in the future or is a non-numeric value)
143	12b	SBP	3	12	Х	Х	Position 1, 2, and 3 are blank or coded as unable to obtain (777), refused (888), missing (999), or out of range (<74; >260)
155	12c	DBP	3	12	Х	Х	Position 1, 2, and 3 are blank or coded as unable to obtain (777), refused (888), missing (999), or out of range (<002; >156)
167	13a	Fast	1	1	X****	X****	Blank, coded as missing (9) if Type = 1 or 2
168	14a	TotChol	3	3	X****	X****	Blank, coded as unable to obtain (777), refused (888), missing (999), or out of range (<44; >702) if Type = 1 or 2
171	14b	HDL	3	3	X****	X****	Blank, coded as unable to obtain (777), refused (888), missing (999), or out of range (<7; >196) if Type = 1 or 2
							Blank, coded as unable to obtain (777), refused (888), missing (999), or out of range (<20 or >380) if Type = 1 or 2
174	14c	LDL	3	3	X****	X****	Note: Any value will be invalid for nonfasting participants who are on lipid-lowering therapy, have a history of high cholesterol, or have a triglyceride level >400 mg/dL

Position	Item Number	MDE Name	Item Length	Field Length	Complete	BP+	Invalid Values (for required items)
177	14d	Trigly	4	4			
181	15a	Glucose***	3	3	X****		Participant is fasting and glucose is blank or coded as unable to obtain (777), refused (888), missing (999) or out of range (<37 or >571), and A1C is blank or coded as unable to obtain (7777), refused (8888), missing (9999) or out of range (<2.8 or >16.2) and Type = 1 or 2; OR participant is not fasting and A1C is blank or coded as unable to obtain (7777), refused (8888), missing (9999) or
184	15b	A1C***	4	4	X****		out of range (<2.8 or >16.2) and Type = 1 or 2
188	16a	BPAlert	1	1			
189	16b	BPDiDate	8	8			
197	17a	RRCComplete****	8	8	Х		Blank
205	18a	RefDate	8	16	Х	Х	Illogical entry (e.g., date is in the future)
221	19a	LSPHCRec	2	2	Х	Х	Blank if referral date is valid
223	19b	Intervention	8	128			
351	19c	LSPHCID	10	160			
511	20a	TobResDate	8	24			
535	20b	TobResType	1	3			
538	20c	TResComp	1	3			
540	End	Complete String	-	-			
				Count	40	31	

^{*} Values are considered not allowable if they are not one of the listed response categories for categorical items

^{**} A string of zeros is not a valid response for this item.

^{***} Only A1c OR Glucose is required for Complete screenings (baseline and rescreening only), recipients do not need to collect both

^{****} Labs may not be medically required for certain participants at follow-up screening, therefore, will not be included in the definition of complete and BP+ at this visit

^{*****} Program flow requires Risk Reduction Counseling at every screening. Date does not need to be entered in MDE file for BP+

c. Submission Procedures

It is important to account for all WISEWOMAN services provided through funding dollars so recipients must submit all data for every participant (e.g., Complete, BP+, and incomplete records).

Please submit only one file containing all screening records. Recipients should upload their submission to the DMS 3.0 as a fixed-format ASCII text file. MDEs must be recorded in the locations identified in the MDE specifications. Each record in the file should represent data for a unique screening visit (baseline screening, follow-up screening, rescreening) with all associated activities. The associated activities may include LSP and/or health coaching (HC) contacts. Each data element must conform to the format and values as specified. Files must include data for the appropriate time period.

For recipients choosing to submit Supplemental LSP/HC data for lifestyle program and health coaching referrals and sessions that exceed the capacity of the MDE file, please read the instructions which can be found in TA Resources under the Library tab inside DMS 3.0 and in Appendix B. Files should be named using the format PPYYMM where PP is the program abbreviation and YYMM is the date of the submission. YY is the two-digit year, and MM is the month from 01 to 12. Recipients should use leading zeros when specifying years and months between 01 and 09. An example of a valid file name is PA1912.

Recipients are encouraged to begin validating their data at least four weeks prior to the submission datehelp and can be reached at <u>WISEWOMANTA@Mathematica-mpr.com</u>.

Data managers for each recipient have been provided with a username and password to log into the web-based WISEWOMAN Data Management System 3.0. Other recipient staff will be provided with a separate username and password upon request. Prior to submission, recipients should prepare bulk data files as instructed for the relevant period and run it through the online validation tool to identify errors and quality checks. These errors and quality checks should be addressed to the extent possible prior to submission. See Appendix B for forms that recipients may submit along with their MDE data file.

As the data contractor prepares the analytic file after programs' final submissions, data issues may be identified for immediate correction. In these instances, project officers will notify programs that there are data issues for correction and will follow up with programs about making these corrections. The project officer will act as a liaison to the data contractor on these issues. Programs will resubmit corrected data through the WISEWOMAN website and notify their project officers.

d. Data Confidentiality and Security

This section describes the data confidentiality and security guidelines for preparing and submitting MDE data. Data and documents submitted via the WISEWOMAN website will be encrypted during transmission. Programs must not send information that will allow participants to be identified and must use encoded identifiers and so on to uniquely identify participants' data. In addition, data submissions must be de-identified pursuant to the Health Insurance Portability and Accountability Act of 1996 (HIPAA).

MDE data are "limited data sets" in which all identifying information has been removed, with the exception of encoded participant ID, county of residence, ZIP code of residence, birth month and year, Hispanic origin, and race. The participant ID must not be linked to any other external datasets containing personal information. Submissions must not include any of the identifiers stipulated in HIPAA.

Recipients are expected to implement data security procedures that will secure participant identifying and health information, including those related to back-up, hardcopy and electronic storage, and transmission. Additional information about CDC data security procedures can be requested.

APPENDIX B: DATA QUALITY AND VALIDATION

CDC is committed to ensuring that the data submitted are accurate, valid, reliable, and complete, and provides recipients with several tools to help monitor and improve data quality. This section describes three items: online validation through the Data Management System 3.0; data validation procedures and forms; and the method for calculating error rates. These items together form a data quality system that allows the identification and validation/correction of out-of-range values, improbable values, and missing data (unknown, refused, and not obtained). It also provides an assessment of data quality through an error rate calculation algorithm.

Validation of Data

Online validation will be available through the WISEWOMAN Data Management System 3.0. Instructions for validating data are available in the WISEWOMAN Quick Reference Manual resource in the "Documents" tab of the Data Management System 3.0.

CDC distinguishes between errors and quality checks using the following definitions.

- Errors are out-of-range and missing values for variables that are critical to
 assessment of program performance, management, and areas for improvement.
 Responses that are not considered programmatically acceptable may also be defined
 as errors.
- Quality Checks are values that seem improbable but are still possible; should be available but are unknown, refused, or unable to be obtained; are not required but are missing; or are contrary to medical guidance.¹ Responses that may be clinically problematic may also be highlighted for quality checks along with values that are programmatically problematic, i.e., values that do not align with program guidance, such as ages outside of 40-64 years.

Prior to data submission, programs should ensure that their data are validated. Programs are encouraged to check on the validity of their data multiple times before the deadline to maximize data quality. Whenever possible, errors should be corrected and quality check values validated before the data are submitted to CDC.

As needed, the online validation provided on the web-based WISEWOMAN website will be updated by the data contractor to reflect any changes in specifications and to account for nuances discovered about the data. Any changes will be documented in the MDE manual and edits documentation.

¹ Valid values for items used to determine a complete or BP+ screening record are provided in Table A.2.

Data Validation Procedures and Forms

Specific response options for some data elements require that recipients provide information in addition to that in the MDE data files. This section describes the procedures and forms that can be used to validate or explain values in the MDE data submitted, to provide explanation for alerts not seen within seven days, to notify CDC of changes in participants' unique IDs, to make corrections to previous MDE data, and report on additional LSP/HC sessions.

Validation or Explanation of Values

When MDE values are flagged as errors, recipients can confirm these values to be valid or provide further explanation about them using the Validation of Data form (recipients are not required to provide further explanation for quality checks). This form can be completed on the web-based WISEWOMAN Data Management System 3.0 at the time of MDE submission and by the submission deadline.

Values for validation or explanation fall into the following general categories:

- Out-of-range values. These will be identified as quality checks or errors. In general, values that are highly unusual will be identified as quality checks, while values that are nearly impossible or are not a response option for a categorical field will be identified as errors. For example, heights less than 48 inches will be flagged as errors. Because such a height would result in an error for this record, the program might confirm this height by submitting an entry in the Validation of Data form and explaining the circumstances of the error.
- Responses coded as participant refused. Although participants are able to refuse
 any question or clinical service, it may be appropriate to inform CDC why the program
 has chosen to include a woman who refuses basic assessment or screening services
 as a participant in the program.
- *Other*. Other errors flagged for which the recipient would like to provide an explanation.

Notification of Participant Unique ID Changes

If the participant unique ID number changes for one or more participants between submissions, recipients must notify CDC of the change by submitting a Participant ID Change Form, which details the participant unique IDs affected. This form can be completed on the web-based WISEWOMAN Data Management System 3.0. Identifying these changes is critical to accurately link records between periods and follow participant changes over time.

Error Rate Calculation Method

This section provides the method used to calculate error rates. The WISEWOMAN website will generate a validation report for immediate viewing through the online validation tool. The report contains an error rate calculated for the entire submission. There are 59 variables, which include variables with multiple components. These components sum up to a total of 72. The error rate is calculated using the following formula:

1. Complete error score calculation:

= # of Errors / (# of Complete Records * 72 components)

2. BP+ error score calculation:

= # of Errors (excluding errors on the 10 MDEs not required for BP+) / (# of BP+ Records * 62 components)

Notes:

- The number of components = 72 10 = 62
- The 10 MDEs required for BP+ but not Complete include: FruitVeg, Fish, Grains, Sugar, SaltWatch, PA, PHQ, Glucose, A1C, RRCComplete
- Errors on the 10 MDEs listed above should be excluded from the numerator

3. Weighted error score calculation:

(Complete Error Rate * (# Complete Records / # Complete & BP+ records)) + (BP+ Error Rate * (# BP+ records / # Complete & BP+ records))

Programs can provide explanations for any errors by submitting to CDC the Validation of Data form shown at the end of this Appendix. The calculation of the final error rate will be conducted following the final submission and review of documentation provided by programs.

Validation of Data Form

The Validation of Data Form should be filled out to validate or explain any values submitted. These values will include mainly those flagged as errors. (See the Documents tab inData Management System 3.0 for a list of errors and quality checks). CDC will review the information provided in this form and consider these values in the calculation of the error rate.

Each value in the form (which is available on the web-based WISEWOMAN Data Management System 3.0) should be reviewed and verified by your program staff. To fill out this form, go to the Miscellaneous Forms tab of the Data Management System 3.0 and select "Go to Validation of Data Form." Select "Create New Validation of Data record" for each MDE item to be validated. The following information is needed for each record:

- **StFIPS.** Provide your state or tribal code for the record to be validated/explained.
- Validation Type. Identify whether the validation or explanation is for an error (E), quality check (Q), or some other issue (O).
- **BPDate.** Provide the BPate for the record to be validated/explained.
- EncodeID. Provide the participant unique ID number for the record to be validated/explained.
- **MDE Item Number.** Provide the MDE item number associated with the error, quality check, or other value for validation/explanation.
- **MDE Value.** Provide the value or code (e.g., numeric value for height, '7 unknown') to be verified/explained.
- **Explanation.** Provide an explanation for the value (e.g., review of hard-copy record, discussion with provider verified value).

Participant ID Change Form

The Participant ID Change Form should be filled out when a participant's Encode ID has changed since a previous submission. The correct Encode ID for a participant is needed to track participant data over time. Each value in the form (which is available on the web-based WISEWOMAN Data Management System 3.0) should be reviewed and verified by your program staff. To complete this form, go to the Miscellaneous Forms tab on the Data Management System 3.0 and select "Go to Participant ID change records." Select "Create New Participant Change Record" for each ID that changed. The following information is needed for each changed ID:

- **StFIPS.** Provide your state or tribal code as entered for the participant with the new Encode ID.
- *OrigEncodelD*. Provide the original participant unique ID number for the participant.
- **NewEncodeID.** Provide the new, changed participant unique ID number for the participant.
- ChangeDate. Provide the date that the EncodeIDs were changed.
- ReassignedDate. If the original EncodeID has been reassigned to a new participant, provide the date of the reassignment here; otherwise, leave this field blank.

Correction to Previous MDE File Form

The Correction to Previous MDE File Form may be filled out when modifications have been made to a screening record that had been previously submitted to CDC. Recipients are not required to submit this form, but may choose to submit it if they would like to provide an explanation to CDC about significant updates or corrections made to previously submitted data.

Each value in the form (which is available on the web-based WISEWOMAN Data Management System 3.0) should be reviewed and verified by program staff. To complete this form, go to the Miscellaneous Forms tab on the Data Management System 3.0 and select "Go to MDE Correction Form." Select "Create New MDE Correction Record" for each record change to be documented. The following information is needed for each corrected record:

- **StFIPS.** Provide your state or tribal code as entered for the participant with the new Encode ID.
- EncodelD. Provide the original participant unique ID number for the participant.
- Office Visit. Provide the office visit date (BPDate) for the screening that the corrections affect.
- **Screening Number.** Provide the number of screenings received by the participant (NScreen) as of the screening that the corrections affect.
- Type of Revision. Select one of the following options from the dropdown menu:
 Added New Records for previous periods, Edited Existing Record, Dropped Records for previous period

Supplemental Lifestyle Program and Health Coaching (LSP/HC) Session Spreadsheet

The current MDE file format allows for documentation of up to two LSP/HC referrals and up to 16 LSP/HC sessions for each screening. If a participant receives more than two LSP/HC referrals and/or attends more than 16 LSP/HC sessions, recipients may choose to record and submit these data to CDC for the purposes of program monitoring and/or evaluation.

Each value in the form should be reviewed and verified by program staff. The form and detailed instructions for completing the form are available under the DMS Documents Library of the WISEWOMAN Data Management System 3.0. The instructions include examples for completing the form when a participant attends more than 16 LSP/HC sessions associated with a screening and when a participant receives more than two LSP/HC program referrals associated with a screening. The supplemental form should be uploaded under the Miscellaneous Forms tab by selecting "Go to Upload Supplemental Forms" and then "Upload New Supplemental Form." The following fields are included the in the form:

- **Screening Number.** Provide the number of screenings received by the participant (NScreen) as of the screening associated with the HC/LSP.
- *EncodelD.* Provide the original participant unique ID number for the participant.
- **BPDate.** Provide the office visit date (BPDate) for the screening (baseline screening or rescreening) that the corrections affect.
- **RefDate.** Provide the date of the HC or LSP referral.
- Intervention. Provide the HC or LSP session dates.

APPENDIX C: DATA ANALYSIS AND USE

MDEs provide a rich source of data for the WISEWOMAN Program. CDC and recipients use MDEs in a variety of ways to monitor and assess progress and performance. This Appendix describes the data summary report generated with every submission and other data uses for the MDEs by CDC. It also discusses potential ways in which recipients can use the data.

Data Summary Report Format and Content

MDE data submissions are used to generate biannual program-specific and aggregate MDE reports. CDC and recipients use these reports to gauge program progress in meeting goals and identify areas for improvement. For example, CDC project officers may use these reports to help identify areas for technical assistance, and recipients may use them to detect areas where further provider training is needed. Uses of MDE data are discussed in greater detail in the subsections below.

Additional information about the data summary report format and content will be provided once available.

Data Use by CDC

WISEWOMAN MDEs support three major objectives: 1) public health practice through continuous program improvement, 2) program performance, and 3) assessing program health outcomes through evaluation.

Potential Data Use by Funded Programs

Recipients use MDEs in a variety of ways to drive program improvement and track program progress. Below are some examples of MDE use among funded programs.

- Analysis of provider performance. Recipients have used MDEs to track the number
 of screenings and LSP/HC sessions conducted by provider sites. In addition, some
 have created program-level performance measures that they calculate for individual
 providers.
- *Identification of areas for provider trainings.* Recipients have used MDEs to identify areas where provider sites were in need of training or technical assistance.
- Assessment of performance in comparison to national benchmarks. Recipients
 have used MDEs to assess the characteristics and risks of the population served in
 comparison to that for their entire state or the nation.
- Assessment of participant changes in risk factors. Recipients have used MDEs to analyze changes between participants' baseline screening, rescreening, and follow-up screening visits.

Recipients interested in receiving technical assistance related to using MDEs as a data source for program monitoring and evaluation should contact their project officer.

APPENDIX D: TECHNICAL ASSISTANCE RESOURCES

To support recipients in collecting and submitting data, CDC has developed several strategies and tools to provide technical assistance to recipients. This appendix describes the various types of technical assistance available to recipients, the web-based WISEWOMAN Data Management System 3.0, the method for requesting individualized technical assistance, and the technical assistance Helpdesk.

Types of Technical Assistance Available

Technical assistance available to recipients can be broadly categorized as individualized technical assistance, group technical assistance, and tools. Below, specific types of technical assistance/tools within these categories are described. The table at the end of this subsection summarizes the types of technical assistance/tools by category, provider, and timeline.

Individualized Technical Assistance

- Data Review Calls. After each MDE submission, summary reports are generated and
 may be reviewed with recipients during a data review call. As needed, data quality
 reports and other materials may also be reviewed.
- Helpdesk Requests. Recipients can request individualized technical assistance
 through the Helpdesk (WISEWOMANTA@mathematica-mpr.com). A health scientist
 from the CDC data team will collaborate with the data contractor to respond to
 technical assistance requests. This type of assistance is tailored to the recipient and
 the question. More information is provided in the following subsections of this
 appendix, "Requesting Individualized Technical Assistance" and "Helpdesk for
 Technical Assistance Requests."

Group Technical Assistance

Ad Hoc Data Calls and Trainings. Throughout the course of the year, data issues
affecting a majority of or all recipients may be identified, either through individualized
technical assistance or as a result of changes to the MDE submission process and
specifications (e.g., modification of MDE specifications, added MDE variables). As a
result, trainings or group communications may be needed. If the need for these
trainings or group communications cannot be fulfilled at the annual meeting, ad hoc
data calls and trainings will be held.

Tools

- WISEWOMAN MDE Manual. This manual is a technical assistance tool for recipients.
 It provides detailed guidance on the MDE submission process and MDE specifications,
 and it will be updated as necessary to stay current with the data submission and
 collection requirements. Recipients can access the current edition in the
 WISEWOMAN Data Management System 3.0 (wwwn.cdc.gov/wisewoman).
- Edits Documentation (SQL Spreadsheet). The edits documentation details all the edits programmed in the validation tool. The documentation provides the coding used for validation in plain language. It also documents the changes to the edits from the previous MDE edition. Recipients can access the current edition in the WISEWOMAN Data Management System 3.0 (wwwn.cdc.gov/wisewoman).

As needed, other tools may be disseminated to recipients.

Summary of Types of Technical Assistance and Tools Available

TA Type	Provider	Timeline
Individual		
Data review calls	Project officers and/or data contractor	Semiannually, after MDE submission and release of data summary reports
Helpdesk requests	Data contractor	As needed
Group		
Ad hoc data calls and trainings	Data contractor	As needed
Tools		
WISEWOMAN MDE Manual	Data contractor	Ongoing
Edits documentation	Data contractor	Ongoing

Helpdesk for Individualized Technical Assistance Requests

Technical assistance may be requested through by emailing the data contractor at <u>WISEWOMANTA@mathematica-mpr.com</u>.1 Once a request for technical assistance related to MDEs is received, Helpdesk will automatically confirm receipt of the request and collaborate with the Health Scientist to resolve the request. For more complex requests or those requiring project officer input, responses may take more than 24 hours.

All requests are tracked by Helpdesk staff and the health scientist; this is to ensure that follow-up is completed for all requests and that responses are satisfactory to the requester. In addition, project officers will be kept abreast of the technical assistance needs of their programs. The tracking of technical assistance requests by the Helpdesk, health scientist and project officers allows CDC to identify common issues to inform Program-wide technical assistance.

¹ Recipients may also choose to telephone individual members of the data contractor team. However, requesting technical assistance through email or website guarantees that all data contractor team members receive notification of the request, and therefore requests are more likely to receive a prompt response.

APPENDIX E: PERFORMANCE MEASURES

- 1. Increased reporting monitoring, and tracking of clinical data for improved identification, management, and treatment of women with high blood pressure
 - Number and percentage of WISEWOMAN participants whose WISEWOMAN provider has a protocol for identifying patients with undiagnosed hypertension.
- 2. Increased use of and adherence to evidence-based guidelines and policies related to team-based care.
 - Number of percentage of WISEWOMAN participants whose WISEWOMAN provider has policies or systems to implement a multi-disciplinary team approach to blood pressure control
- 3. Increased use of data systems to identify and refer at risk women to appropriate healthy behavior support services.
 - Number and percentage of at-risk women in WISEWOMAN referred to an appropriate healthy behavior support service
- 4. Increase data sharing and utilization (e.g. through a bi-directional feedback mechanism)
 - Number and percentage of WISEWOMAN providers with an implemented community referral system (tracking bi-directional referrals) for healthy behavior support services for people with high risk for CVD.
- 5. Increased participation in healthy behavior support services resulting in improved and maintained healthy behaviors and lifestyle changes.
 - Number and percentage of women in WISEWOMAN referred to a healthy behavior support service who attend at least one session.
- 6. Improved blood pressure control
 - Number and percentage of women in WISEWOMAN with known high blood pressure who have achieved or are currently maintaining blood pressure control.

APPENDIX F: NUTRITIONAL PROMPTS

American Heart Association Handout

Item 7a: FruitVeg

Examples of 1 cup serving of fruit:







1 small apple

1 medium pear

8 large strawberries

2 large plums









Examples of 1 cup serving of vegetables:







12 baby carrots (or 2 medium carrots)


2 large stalks of celery

1 large sweet potato










Item 7b: Fish

Examples of 1 serving of fish

7oz canned tuna



8oz salmon steak



Item 7c: Grains

Examples of 1 serving of whole grains:

½ cup oatmeal



3 cups popcorn



1 slice whole wheat bread



½ cup brown rice



Item 7d: Sugar

Example:



36 oz (450 calories) of sugar sweetened beverages



1 teaspoon of sugar (4 grams) added to tea/coffee x 28 times = 450 calories

Items: 7f (AlcFreq) and 7g (AlcDay)

Examples of 1 alcoholic drink:

12 fluid ounces of beer



8-9 fluid ounces of malt liquor



5 fluid ounces of wine



1.5 fluid ounce shot of spirits (e.g., whiskey, gin, vodka, rum, tequila)



about 40%

Item 8a: PA (Physical Activity)

Examples of physical activity:

Walking briskly



Water aerobics



General gardening



Race-walking, jogging, or running



Bicycling



Aerobic dancing

